

| Authors | Publication title | Date | Journal | Funding acknowledgement | Competing Interests | If relevant: clinical trial ID | Comments | Date of data extraction |
|--------------------------------------|--|--------------|---|---|--|---|---|-------------------------|
| Afolabi MO | Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supra-physiological temperatures in carbohydrate glass | 2016 | Official journal of the American Society of Gene & Cell Therapy | Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), a four and a half year integrated project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP, grant number IP-2008.31100.003). The work was also supported by the UK National Institute of Health Research (NIHR) through the NIHR Oxford Biomedical Research Centre (http://www.oxfordbiocentre.org/) (J453201 Adjuvaccine). The Wellcome Trust (http://www.wellcome.ac.uk/) (084113/Z/07/2) and the Medical Research Council. Co-funding was also provided by the Swedish International Development Cooperation Agency (Sida) and Irish Aid. This research was supported by the UK Medical Research Council (MRC) and the Department for International Development (DFID) under the MRC/DFID Concordat agreement and MC_UP_A00001122 | AVSH is a named inventor on patent applications on malaria vectored vaccines and immunization regimens. Authors from ReThera are employees of and/or shareholders in ReThera, which is developing vectored vaccines for malaria and other diseases. | NCT01373879, NCT01450293, NCT01635647, PACTR201204000362870, PACTR201401000363170, PACTR201208000404131 | N/A | 08/12/2020 |
| Alcock R | ChAdOx1 and MVA based vaccine candidates against MERS-CoV eliciting neutralising antibodies and cellular immune responses in mice | 2010 | Elsevier - Vaccine | No funding disclosure found | Conflict of interest: SCG is a co-founder of, consultant to and shareholder in Vac-ctech plc which is developing vectored influenza and MERS vaccines. | N/A | No funding disclosure found | 16/12/20 |
| Alharbi NK Alharbi NK | Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens | 2019 2017 | Nature Clinical and Vaccine Immunology | This study is funded by KAIMRC, project RC16/093 granted to the PI: Naif Khalaf Alharbi; in addition, animals, research farm, and animal logistics were financially supported by MEWA, Saudi Arabia. SCG is a Jenner Investigator and supported the manufacturing of the vaccine batch. | SCG is a co-founder of, consultant to and shareholder in Vacctech plc which is developing vectored influenza and MERS vaccines. | N/A | N/A | 21/12/2020 |
| Alves E | Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens | 2017 | Clinical and Vaccine Immunology | The work was funded by a Wellcome Trust Career Development Fellowship award (grant number 097395/Z/11/Z) to A.R.-S. | N/A | N/A | N/A | 08/12/2020 |
| Antrobus RD Asthagiri Arunkumar G | Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice | 2019 | Molecular Therapy Elsevier Vaccine | The study was funded by grants from the UK MRC, the NIHR through the Oxford Biomedical Research Centre, and the Oxford Martin School. The study was funded by an MRC Biomedical Catalyst DPFS, DC5 award (MR/N063772/1). In addition, this study was partially funded by the NIAD Centers of Excellence for Influenza Research and Surveillance contract (CEIRS, HHSN27201400080C). Andriani Ioannou was supported by an NIAD T32 Virus-Host Interactions training grant (5T32AI007647-17). The work was funded by a Wellcome Trust Career Development Fellowship award (grant 097395/Z/11/Z) to A.R.-S., who is also a Jenner Investigator and an Oxford Martin Fellow and is supported by MRC-DPFS (grant MR/N019008/1). A.M.S. was funded by EVIMALAR's program funding (FP7/2007-2013) under grant agreement number 242095. E.A. was funded by CAPES from Science without Border program. A.V.S.H. is supported by a Wellcome Trust grant (number 095540/Z/11/Z) and is a Jenner Investigator and an Oxford Martin Fellow. | T.I. is an Oxford Martin fellow. S.C.G. and A.V.S.H. are Jenner Investigators. S.C.G., M.D.D. and A.V.S.H. named inventors on a patent application describing the ChAdOx1 vector (GB Patent Application No. 1108879.6). The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines with Florian Zimmer being an inventor. Sarah Gilbert is an inventor on patents covering ChAdOx1 and MVA-NP-M1, filed and owned by the University of Oxford, and is a co-founder of and consultant to Vacctech, a University of Oxford spin-out company which is undertaking advanced clinical development of viral vectored influenza vaccines. | NCT01623518 | N/A | 08/12/2020 |
| Atcheson E | Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors | 2018 | Infection and Immunity | N/A | N/A | N/A | N/A | 10/12/2020 |
| Barnes E Barnes E | Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man ChAdOx1-HBV therapeutic vaccine: Phase 1 study results in healthy volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites | 2012 | Science Translational Medicine | European Union (Framework VI:HEPACIVAC), Medical Research Council (UK), Wellcome Trust, Oxford NIHR Biomedical Research Centre, James Martin School for 21st Century, Oxford, Wellcome Trust Clinical Research Facility, Birmingham; National Institute for Health and Research Liver Biomedical Research Unit, Birmingham; and NIH grant 1U19AI082630-01. | S. Colocca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee ad-enovirus vectors (WO 2006139911 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirus vaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine). P.K. has acted as a consultant to Tibotec and Pfizer on antiviral therapy. Authors from Okairos are employees of and/or shareholders in Okairos. The other authors declare that they have no competing interests. | NCT01070407, 2007-004259-12 | N/A | 10/12/2020 |
| Bauza K | Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection | 2012 | Plos One | N/A - only on clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT02042979) | N/A | NCT04297917 | Study still recruiting | 18/12/20 |
| Betts G | Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure | 2014 | Plos One | The work was funded by a Wellcome Trust Career Development Fellowship award, grant number 097395, to A.R.-S. A.R.-S. and A.V.S.H. are Jenner Investigators and Oxford Martin School Fellows. E.Y.J. and T.M. are funded by the Medical Research Council and Cancer Research United Kingdom. Work at the Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number WT098051. | N/A | N/A | N/A | 10/12/2020 |
| Biswas S | Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1 | 2011 | Plos One | Funding was provided by NEWTRAC (EC FP7), HM, AH and AR-Sare Jenner Institute Investigators. AR-S is a Wellcome Trust Career Development Fellow (097395). This work was supported by the UK Medical Research Council (MRC; http://www.mrc.ac.uk/) [grant number G0700735]; the EMVDA (European Malaria Vaccine Development Association; http://www.emvda.org), a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbiocentre.org/); and by VIMAR (http://www.vimar.org) funded by the European Community's Seventh Framework Programme (FP7/2007-2013) [Grant agreement No. 242095]. The GIA work was supported by the PATH Malaria Vaccine Initiative (http://www.malaria-vaccine.org) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov). SIdH holds a Wellcome Trust Research Training Fellowship (097940/Z/11/Z). AVSH and SID are Jenner Investigators (http://www.jenner.ac.uk). SB is a NDM Leadership Fellow (http://www.ndm.ox.ac.uk) and Junior Research Fellow of St Catherine's College, Oxford University (http://www.stcats.ox.ac.uk). SID is a UK MRC Career Development Fellow (G1000327) and Lister Institute Research Prize Fellow (http://www.lister-institute.org.uk). The funders had no role in study design, data collection and analysis, decision to | SCG, KAC, AVSH and SID are named inventors on patent applications covering malaria vaccines and immunization regimens (Adenoviral vectors encoding a pathogen or tumour antigen, WO/2008/122811; Viral vector immunogenic compositions, GB1015471.3). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. | NCT01095055, NCT01003314, NCT01142765, NCT00890760 | N/A | 10/12/2020 |
| Biswas S | Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP | 2018 | Scientific Reports | SB was funded by MalPaTraining, an FP6-funded Marie Curie Action under contract number MEST-CT-2005-020492. The GIA work was supported in part by the PATH-MVI Malaria Vaccine Initiative (MVI) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases and in part by the EMVDA (European Malaria Vaccine Development Association, a European Commission FP6-funded consortium). AAM is funded by the UK Medical Research Council (1U17S32067). AVSH and SCG are Jenner Investigators and are funded by the Wellcome Trust. SID is a Junior Research Fellow at Merton College, Oxford University. | SID, SCG and AVSH are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. Authors from Okairos are employees of and/or shareholders in Okairos, which is developing vectored malaria vaccines. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. | N/A | N/A | 10/12/2020 |
| Bliss CM Bliss CM | Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice | 2020 | Molecular Therapy | This study was funded by the UK NIHR Biomedical Research Centre (BRC) with additional support from the Wellcome Trust. This research project was supported in part by funding from NIHR/NIAD CEIRS (HHSN272201400090C), and by grants awarded to L.C., including the US Graduate Women in Science (GWS) 2017 Neil Mondy and Monique Braude Fellowship, a UK Royal Society for Tropical Medicine and Hygiene small grant (G00050), and by a Medical Research Fund pump-priming grant from the University of Oxford (MR/R017205/2/150), United Kingdom. | A.V.S.H. is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and is a co-founder of, consultant to and shareholder in Vacctech plc, which is developing Ad-vectored vaccines. The remaining authors declare no competing interests. | N/A | N/A | 10/12/2020 |
| Borthwick N | Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1 | 2014 | Molecular Therapy | The work was supported by Medical Research Council (MRC) UK and Department for International Development UK through an Experimental Medicine call II award G0701669 with contributions from the International AIDS Vaccine Initiative. HIV-1 infectious molecular clones were obtained from Dr George Shaw, University of Pennsylvania. The FEC Control Peptide Pool was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (ref. no. 19626). | A.N. and S.C. who were employees and shareholders of Okairos and Advent during the conduct of the study, and are inventors on patents WO 2005071093 (A3), WO 2006139911 (A3) and WO 03031588 (A2). A.I. KAM, who reports grants from MRC and NIH, personal fees from International AIDS Vaccine Initiative SAB during the conduct of the study and is an inventor on patent WO 06123256, LC reports grants from MRC during the conduct of the study, and T.H. who reports grants from MRC and European and Developing Countries Clinical Trial Partnership obtained during the conduct of the study and is an inventor on patent WO 06123256. The other authors declare no conflict of interest. | No ID found | Tried searching clinicaltrials.gov but could not find registered trial and not in study | 16/12/20 |

| | | | | | | | |
|---------------|--|---------------------------------------|--|--|----------------------------|---|------------|
| Bowyer G | Activation-induced Markers Detect Vaccine-Specific CD4 ⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials | 2018 Vaccines | The clinical trial was supported by funding from an Enhancement Award to a Wellcome Trust Strategic Award (to AVSH as PI) co-funded by the UK Medical Research Council, the UK Department for International Development and the European and Developing Countries Clinical Trials Partnership, with additional funding from the NIHR Oxford Biomedical Research Centre. The Oxford clinical trial was supported by funding from an Enhancement Award to a Wellcome Trust Strategic Award (to A.V.S. Hill as principal investigator) cofunded by the UK Medical Research Council, the UK Department for International Development, and the European and Developing Countries Clinical Trials Partnership, with additional funding from the National Institute for Health Research Oxford Biomedical Research Centre. GlaxoSmithKline Biologicals SA supplied the ChAd3-EBO-Z vaccine and had the opportunity to review this manuscript. The MVA-EBO-Z vaccine was biomaterialized for these trials by Emergent Biosolutions under a contract from Oxford University with funding from the same Enhancement Award. The Senegal trial was largely funded by a European Commission Horizon 2020 project award, EbolaVAc (http://www.ebolavac.eu), grant agreement no. 666085. | A.V.S.H. is a named inventor on patents relating to viral vectored vaccines. All other authors declare no conflicts of interest. | NCT02451891, 2015-000593-3 | N/A | 21/12/2020 |
| Bowyer G | Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus | 2020 JEM | | N/A | NCT02451891 | N/A | 18/12/20 |
| Boyd AC | Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates | 2013 Elsevier - Vaccine | The Biotechnology and Biological Sciences Research Council and Wellcome Trust are gratefully acknowledged for their financial support. | N/A | N/A | N/A | 16/12/20 |
| Bull TJ | Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates | 2014 Veterinary Research | This work was supported by Biotechnology and Biological Sciences Research Council (BBSRC) grants BB/H010556/1 and BB/H010718/1. Jayne Hope and Irene McGuinness were supported by Institute Strategic Grant funding from the BBSRC | TJB is a minor shareholder in HAV Vaccines Ltd. | N/A | N/A | 20/12/2020 |
| Capone S | ST4 oncofetal glycoprotein: an old target for a novel prostate cancer immunotherapy | 2010 Elsevier - Vaccine | This work was supported by the Wellcome Trust. AVSH is a Wellcome Trust Principal Research Fellow. | N/A | N/A | N/A | 16/12/20 |
| Cappuccini F | Safety and immunogenicity of novel ST4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial | 2017 Oncotarget | This work was supported by Oxford National Institutes for Health Research (NIHR) Biomedical Research Centre, UK (IR), the UK Medical Research Council CIG award (SS), the UK Wellcome Trust Senior Investigator's Award (AVSH) and the European Union's Seventh Framework Programme under grant agreement No. 602705 (FC, EP). | N/A | N/A | N/A | 21/12/2020 |
| Cappuccini F | Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer | Journal for ImmunoTherapy of Cancer | The VANCE clinical trial was supported by the European Union's Seventh Framework Programme under grant agreement no. 602705. | AVSH is a co-founder and shareholder in Vacitech Ltd which has supported the Oxford prostate cancer vaccine programme. | NCT02390063 | N/A | 18/12/20 |
| Cappuccini F | Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route | 2016 Cancer Immunol Immunother | This work was supported by Oxford National Institutes for Health Research (NIHR) Biomedical Research Centre, UK (I. Redchenko); the UK Medical Research Council CIG award (S. Stolbiling), the UK Wellcome Trust Senior Investigator's Award (A.V.S. Hill) and the European Union's Seventh Framework Programme under Grant Agreement No. 602705 (F. Cappuccini, E. Pollock) | N/A | N/A | N/A | 21/12/2020 |
| Carey JB | Micro-needle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route | 2014 Scientific Reports | This work was supported by Enterprise Ireland (Commercialisation Fund, CF2007/117) and Science Foundation Ireland (National Access Programme 70 and 170). AVSH and SID are Jenner Investigators; and SID is a UK MRC Career Development Fellow (G1000527) and Lister Institute Research Prize Fellow. | The authors declare no competing financial interests. AVSH and SID are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. JBC, AV, COM, AVSH, ACM are named inventors on patent applications covering micro-needle-mediated vaccine delivery. | N/A | N/A | 16/12/20 |
| Colloca S | Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species | 2012 Science Translational Medicine | This work was supported in part by Hepacivac (LSH-2005-1.2.4-2 project 037435) and the Wellcome Trust. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship, E.B. was supported by Medical Research Council (UK) Author | N/A | N/A | Clinical trials not this study but referenced studies | 16/12/2020 |
| Colston JM | Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination | 2016 The Journal of Immunology | This work was supported by Wellcome Trust Grants 098972/12/A and 091663MA. | N/A | N/A | N/A | 20/12/2020 |
| Cottingham MG | Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors | 2012 Biotechnology and Bioengineering | This work was supported by the European Vaccine Initiative, the Oxford Martin School, the Gates Foundation through the Foundation for NIH, the Wellcome Trust, and the NIHR Oxford Biomedical Research Centre. We are grateful to Dr. Alexandra J. Spencer, Jenner Institute, University of Oxford, for assistance with immunology; to Mr. Jake Matthews, Vector Core Facility, Jenner Institute, University of Oxford, for assistance with ChAd63-Pf230; and to Dr. Nicola K. Green and Dr. Eleanor Berrie of the Clinical Biomanufacturing Facility, University of Oxford, for assistance and advice. Dr. David H. Wylie, Jenner Institute, University of Oxford performed some of the steps. | Conflict of interest: Okairis Srl and the University of Oxford hold intellectual property related to adenovirus vaccine vectors. | N/A | N/A | 16/12/20 |
| Coughlan L | Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults | 2018 Elsevier | Medical Research Council UK, NIHR BMRC Oxford. | SG and AWI are co-founders of Vacitech, a company developing viral vectored vaccines including broadly cross-reactive influenza vaccines. SG holds stock in Sanofi Pasteur which develops and markets influenza vaccines. HDG received a travel grant from Abbvie. | NCT01818362 | N/A | 18/12/20 |
| de Barra E | A phase I study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS | 2014 Plos One | The study was funded by a grant from the European Vaccine Initiative (EVI) (http://www.evivaccine.eu/). Antibody assays were performed at WRAIR and were funded by the Malaria Vaccine Initiative. This work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (A91301 Adult Vaccine) and the Wellcome Trust (084113/Z/07/Z). SCG and AVSH are Jenner Investigators; AVSH is supported by a Wellcome Trust Principal Research Fellowship (45486/Z/05); and SHH holds a Wellcome Trust Research Training Fellowship (097940/Z/11/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | The authors have read the journal's policy and have the following conflicts: AVSH and SCG are named inventors on patent filings related to immunisation with vectored malaria vaccines, specifically WO2008/122769. None of these products have been commercialised. AW was an employee of Okairis AG at the time of the study. Okairis AG has since been acquired by GSK Vaccines, which now owns patents and patent applications related to simian adenoviruses. None of the authors have had any consultancies relevant to this paper. This conflict of interest does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. | NCT01450280 | N/A | 16/12/20 |
| de Cassan SC | The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunisation with a recombinant adenovirus | 2011 The Journal of Immunology | S.C.d.C. is a Ph.D. student supported by the European Malaria Vaccine Development Association, a European Commission Framework Programme 6-funded consortium (LSMR-CT-2007-037396). This work was also partly supported by the Wellcome Trust (Grant 084113/Z/07/Z), the National Institute for Health Research Oxford Biomedical Research Centre, TRANSVAC, a European Commission Framework Programme 7-funded consortium infrastructure grant, and grants to C.E.C. and V.S.C. from the Department of Biotechnology, Government of India, and European Vaccine Initiative. C.E.C. is supported by a Tata Innovation Fellowship from the Department of Biotechnology, Government of India. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship. S.C.G., A.V.S.H., and S.J.D. are Jenner Investigators. S.J.D. is a Medical Research Council Career Development Fellow (Grant G1000527). | Disclosures: S.C.d.C., E.K.F., A.D.D., A.M., S.C.G., A.V.S.H., and S.J.D. are named inventors on patent applications covering malaria-vectored vaccines and immunization regimens. The other authors have no financial conflicts of interest. | N/A | N/A | 16/12/20 |
| Dicks MD | Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice | 2015 Scientific Reports | This work has been funded by a grant from the Wellcome Trust (095540/Z/11/Z). AVSH and SCG are Jenner Institute Investigators. AIS and MGC are James Martin Fellows. | MDID, SCG, AVSH, and MGC are named inventors on a patent application describing the ChAdOx1 vector (US2015044766). | N/A | N/A | 20/12/2020 |
| Dicks MD | The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species | 2015 Vaccine | This work has been funded by the Wellcome Trust (095540) with additional funding from the Foundation for the National Institute of Health through the Grand Challenges in Global Health Initiative (H1LISGCOH). MDID received additional funding from the European Malaria Vaccine Development Association (EMVDA). AVSH is a Wellcome Trust Principal Research Fellow. EG and BC were funded by the Biotechnology and Biological Sciences Research Council BBS/E/I/00001373, United Kingdom. | MDID, SCG, AVSH, and MGC are named inventors on patent applications describing the ChAdOx1 vector (PCT Application No. PCT/GB2012/000467). | N/A | N/A | 20/12/2020 |

| | | | | | | | |
|-----------------------------|---|--------------------------------------|---|---|--|-----|------------|
| Dicks MD | A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle | 2012 Plos One | This work has been funded by grants from the Foundation for the National Institute of Health through the Grand Challenges in Global Health Initiative, with additional funding from the Wellcome Trust. MGID received additional funding from the European Malaria Vaccine Development Association (EMVDA). MGCS is a fellow of the Oxford Martin School Institute for Vaccine Design. SCG is a Jenner Investigator. AVSH is Director of the Jenner Institute and a Wellcome Trust Principal Research Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | Competing interests: MGID, SCG, AVSH, and MGC are named inventors on a patent application describing the ChAdOx2/ChAdOx1 vector (GB Patent Application No. 1108879.6). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. | N/A | N/A | 16/12/20 |
| Draper SJ | Analysis of human B-cell responses following ChAdE3-MVA MSP1 and AMA1 immunization and controlled malaria infection | 2010 The Journal of Immunology | This work was funded by the Wellcome Trust and the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium. S.J.D. is a Junior Research Fellow of Merton College, Oxford, United Kingdom. S.C.G. and A.V.S.H. are Jenner Investigators, and A.V.S.H. is also a Wellcome Trust Principal Research Fellow. | Disclosures: S.J.D., S.C.G. and A.V.S.H. are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. S.C., M.N., A.F., and A.N. are employees of and/or shareholders in Okavios, which is developing vectored vaccines for malaria and other diseases. | N/A | N/A | 16/12/20 |
| Dulali P | Analysis of human B-cell responses following ChAdE3-MVA MSP1 and AMA1 immunization and controlled malaria infection | 2016 Vaccine | This study was conducted with support from a grant from the Bill & Melinda Gates Foundation Grand Challenges Exploration initiative to GMW (OPP1096889) and a Wellcome Trust Fellowship to GMW (WT09835). S.C. and A.V.S.H. are Jenner Investigators. | N/A | N/A | N/A | 20/12/2020 |
| Elias SC | Analysis of human B-cell responses following ChAdE3-MVA MSP1 and AMA1 immunization and controlled malaria infection | 2013 Immunology | This work was supported by the UK Medical Research Council (grant number G0700735); the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford Biomedical Research Centre; the Wellcome Trust (08413/2072); and by CVI/MaAa funded by the European Community's Seventh Framework Programme (FP7/2007-2013) (Grant agreement No. 242095). AVSH and SID are Jenner Investigators; and SID is a UK MRC Career Development Fellow (G1000527) and Lister Institute Prize Research Fellow. | SCG, KAC, AVSH and SID are named inventors on patent applications covering malaria vaccines and immunization regimens. | NCT01373879, NCT01142765, NCT01003314, NCT01095055 | N/A | 20/12/2020 |
| Ewer K | A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA | 2016 New England Journal of Medicine | Supported by the Wellcome Trust, the United Kingdom Medical Research Council, the United Kingdom Department for International Development, and the United Kingdom National Institute for Health Research Oxford Biomedical Research Centre. The National Health Service Blood and Transplant and Public Health England provided funding for the competition ELISA. The ChAd3 vaccine was provided by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline. MVA-BN Filo was produced under a contract (FBS-004-000) between the NIAID and Fisher BioServices and a contract (H4SN27220800044C) between the National Institutes of Health and Fisher BioServices. | Dr. Ballou, Dr. De Ryck report personal fees and other support from GlaxoSmithKline outside the submitted work. Dr. Colocca, Dr. Cortese, Dr. Nicosia reports a pending patent related to chimpanzee adenovirus-vector based filovirus vaccine (WO/2011/130627). Dr. Draper reports grant support from the UK Medical Research Council during the conduct of the study, and non-financial support from GlaxoSmithKline/Okavios outside the submitted work. In addition, Dr. Draper reports pending patents related to viral vector immunogenic compositions (WO 2012042279 A3) and adenoviral vectors encoding a pathogen or tumor antigen (WO 200812811 A2). Dr. Gilbert reports patents related to prime boost immunization with viral vectors. Dr. Hill reports a patent related to heterologous prime-boost immunization, licensed to Oxford BioMedica. Ms. Lella reports other support from the NIHR during the conduct of the study. Dr. Levine reports grant support from Oxford University during the conduct of the study. Dr. Pollard reports grant support from the Wellcome Trust during the conduct of the study, and grant support from GlaxoSmithKline outside the submitted work. | N/A | N/A | 20/12/2020 |
| Ewer K Fedotkyk S | Protective CD8 p T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation | 2013 Nature Communications | The study was funded by grants from the UK MRC, the NIHR through the Oxford Biomedical Research Centre, and the Wellcome Trust. AVSH was supported by a Wellcome Trust Principal Research Fellowship. A.L.G. was supported by a grant from the MRC (G0600424). A.V.S.H., A.R.-S., S.J.D. and S.C.G. are Jenner Institute Investigators; A.V.S.H. is a Wellcome Trust and NIHR Senior Investigator. | Sarah Gilbert, Arturo Reyes-Sandoval, Anna Goodman, Geraldine O'Hara and Adrian Hill are named inventors on patent applications covering malaria vectored vaccines and immunization regimens including WO/2008/122811 Adenoviral vectors encoding a pathogen or tumour antigen and WO/2008/122769 Adenoviral vector encoding malaria antigen. Authors from Okavios are employees of and/or share holders in Okavios which is developing vectored malaria vaccines. All other authors declare no competing financial interests. | N/A | N/A | 16/12/20 |
| Folegatti P.M. | Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entry-disinfectable product-contact components | 2019 Elsevier Vaccine | This work was supported by Merck KGaA, the UK Medical Research Council (grant MR/R017339/1), and the UK Engineering and Physical Sciences Research Council (grant EP/R013756/1). ADD is supported by the Wellcome Trust (grants 201477/16/Zand 204826/76/Z) and is a Jenner Investigator. The study was performed in collaboration between the University of Oxford and Merck KGaA, both partners reviewed the manuscript prior to sub-mission. The other funders had no input to the design of the study or decision to publish. | ADD, SIM, and SCG are named inventors on patent filings relating to the use of simian adenoviruses, but not directly related to the work described here. SCG is a founder of Vaccitech Ltd, which develops adenovirus-vectored vaccines. | N/A | N/A | 10/12/2020 |
| Folegatti P.M. | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial | 2020 The Lancet | UK Department of Health and Social Care, using UK Aid funding, managed by the UK National Institute for Health Research. This project was funded by the UK Department of Health and Social Care (project number 16107/03). The views expressed are those of the authors and not necessarily those of the Department of Health and Social Care. The work was supported by the UK National Institute for Health Research through the Oxford Biomedical Research Centre. The Coalition for Epidemic Preparedness Innovations provided funding for the extended 12 months of follow-up in this study. This study was also partially supported by the Coordenacao de Aperfeiçoamento de Pessoal de Nível Superior, Brazil (finance code 001). The pseudovirus neutralising antibody work was funded by a grant from the Korean Ministry of Health and Welfare (H15C2971) | AH and SG are co-founders of, consultants for, and shareholders in Vaccitech, which is developing adenoviral vectored vaccines. PMF and TL are consultants for Vaccitech. All other authors declare no competing interests. | NCT03399578 | N/A | 18/12/20 |
| Folegatti P.M. Folegatti PM | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial | 2020 The Lancet | UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Centre for Infection Research (DZIF), Partner site Gießen-Marburg-Langen. This work is funded by UK Research and Innovation (MC_PC_19055), Engineering and Physical Sciences Research Council (EP/R013756/1), Coalition for Epidemic Preparedness Innovations (CEPI), the National Institute for Health Research (NIHR), the NIHR Oxford Biomedical Research Centre, and the German Centre for Infection Research (DZIF), Partner site Gießen-Marburg-Langen. Additional resources for study delivery were provided by NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; the NIHR Imperial Clinical Research Facility; and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks and NIHR Oxford Health Biomedical Research Centre. PMF received funding from the Coordenacao de Aperfeiçoamento de Pessoal de Nível Superior, Brazil (finance code 001). Development of SARS-CoV-2 reagents was partially supported by the US National Institute of Health and by HAV Vaccines Ltd. The research was supported by the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR, the NIHR or the Department of Health. | AVSH is a co-founder of and consultant to Vaccitech and is named as an inventor on a patent covering design and use of ChAdOx1-vectored vaccines. AF is a member of ICV, Chair of the WHO European Technical Advisory Group of Experts on Immunisation, an ex-officio member of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Research Network. KMP reports grants from the NIHR Imperial Biomedical Research Centre and Glaxo Sciences, and personal fees from Sanofi Pasteur, outside of the submitted work. MS reports grants from Janssen, GlaxoSmithKline, MedImmune. | NCT04324606. The study is ongoing, and the final manuscript before submission was registered at ISRCTN, 15281137, and in declaration of interests says royalties paid to AZ for vectors. | N/A | 18/12/20 |
| Forbes EK | Safety and immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine | 2019 MDPH | This work was funded by the Wellcome Trust and the EMVDA (European Malaria Vaccine Development Association), a European Commission FP6-funded consortium. The research leading to these results has also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement No 242095. In addition, this work was supported in part by the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, and also by the PATH Malaria Vaccine initiative who support the GIA Reference Center. AVSH and SID are Jenner Investigators. AVSH is a Wellcome Trust Principal Research Fellow. SID is a MRC Career Development Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, except that the design of the rabbit study and the GIA analysis was performed following discussion with PATH MVA. | AVSH is a co-founder and Medical Officer for HAV Vaccines Ltd. S.C.G. and A.V.S.H. are co-founders of, consultants to and shareholders in Vaccitech plc which is developing adenoviral vectored vaccines. | NCT03027193 | N/A | 18/12/20 |
| Gilbert SC Gola A | T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of Cb-binding protein Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimens | 2002 Elsevier - Vaccine | This work was supported primarily by grant G0600424 from the Medical Research Council (ALG) and in addition by Transmoltoc (EU FP7) and BBSRC (award number LDAD_P15820). SID and AVH are Jenner Investigators. SID is a MRC Career Development Fellow. AVH is a Wellcome Trust Principal Research Fellow. ALG was an MRC clinical training fellow whilst she undertook this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. http://www.mrc.ac.uk/ , http://www.bbsrc.ac.uk/ , http://www.wellcome.ac.uk/ . | A.V.S.H., A.G., A.A.W., and A.M.S. are inventors on a patent application PCT/GB2017/051009 submitted to the Oxford University Innovation Limited that covers prime and target vaccination with viral vectors | N/A | N/A | 14/12/20 |
| Goodman AL | Prime and target immunization protects against liver-stage malaria in mice | 2018 Science Translational Medicine | This work was supported primarily by grant G0600424 from the Medical Research Council (ALG) and in addition by Transmoltoc (EU FP7) and BBSRC (award number LDAD_P15820). SID and AVH are Jenner Investigators. SID is a MRC Career Development Fellow. AVH is a Wellcome Trust Principal Research Fellow. ALG was an MRC clinical training fellow whilst she undertook this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. http://www.mrc.ac.uk/ , http://www.bbsrc.ac.uk/ , http://www.wellcome.ac.uk/ . | Author contributions: . Contributed reagents/materials/analysis tools: SB ALGRIP FH. | N/A | N/A | 16/12/20 |
| | A viral vectored prime-boost immunization regime targeting the malaria Pfz25 antigen induces transmission-blocking activity | 2011 Plos One | N/A | N/A | N/A | N/A | 16/12/20 |

| | | | | | | | |
|------------------------------|--|---|--|---|------------------------------|-----|------------|
| | | | This study was supported by UKRI Engineering and Physical Sciences Research Council (EPSRC) award EP/R013756/2 (Vaxiva), UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme and Core Capability Grants to The Pirbright Institute (BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/00007037 and BBS/E/I/00007039), and the Bill and Melinda Gates Foundation supported Pirbright Livestock Antibody Hub (Grant No. OPP1215550). Development of SARS-CoV-2 reagents was partially supported by the NIAD Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C and EPSC Grant No. EP/S025243/1 to the Rosalind Franklin Institute. A.L., G.W., C.B., A.B., A.B. and V.M. are supported by the UK Department for Environment Food & Rural Affairs. We thank V. Clark, H. Gray, and R. Smith for animal husbandry and the Jenner Institute Vector Core Facility for assistance, and The Pirbright Institute Animal Services Team for animal care and provision of samples. | S.C.G. and T.L. are named on a patent application covering ChAdOx1 nCoV-19. The remaining authors declare no competing interests. The funders played no role in the conceptualisation, design, data collection, analysis, decision to publish, or preparation of the manuscript. | N/A | N/A | 18/12/20 |
| Graham SP | Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 | 2020 Nature partner journals | | | | | |
| Halbroth BR | Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8(+)-T Cell Responses | 2018 Scientific Reports | This work was supported by the EMVDA (European Malaria Vaccine Development Association), a European Commission (EC) FP6-funded consortium (LSHP-CT-2007-027506), the UK National Institute of Health Research through the Oxford Biomedical Research Centre (BHR-BC) (A91301 Adult Vaccine); the Wellcome Trust (084113/Z/07/Z); and EVIMaLAR, an EC FP7-funded programme (Grant agreement No. 242095). The G1A work was supported by the PATH Malaria Vaccine Initiative and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. | A.V.S.H. is a named investigator on US 12/595 574 and UK PCT/GB2008/01262 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimens; A.V.S.H., A.J.S., M.J.C. and B.R.H. are named investigators on UK PCT/GB2014/055596, a novel molecular adjuvant application. | N/A | N/A | 10/12/2020 |
| Hodgson SH | Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial | 2014 Molecular Therapy | This work was supported by the PATH Malaria Vaccine Initiative, the United Kingdom National Institute of Health Research through the Oxford Biomedical Research Centre (grant A91301 Adult Vaccine), and the Wellcome Trust (grants 084113/Z/07/Z and 054848/Z/05 to A.V.S.H. and grant 097940/Z/11/Z to S.H.H.). | D.D., J.J.I., S.C.J.C., A.V.S.H., and S.J.D. are named inventors on patent applications covering malaria vaccines and immunization regimens. A.N. is an employee of and/or shareholder in Okairo, which is developing vectored vaccines for malaria and other diseases. | NCT01351948 | N/A | 20/12/2020 |
| Hodgson SH | Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naïve individuals | 2015 The Journal of Infectious Diseases | This work was supported by the PATH Malaria Vaccine Initiative, the United Kingdom National Institute of Health Research through the Oxford Biomedical Research Centre (grant A91301 Adult Vaccine), and the Wellcome Trust (grants 084113/Z/07/Z and 054848/Z/05 to A.V.S.H. and grant 097940/Z/11/Z to S.H.H.). | A.V.S.H. and S.C.G. are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. S.C. and A.N. are employees of and/or shareholders in Okairo, which is developing vectored vaccines for malaria and other diseases. All other authors report no potential conflicts. | NCT01623557 | N/A | 20/12/2020 |
| Kelly C | Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans | 2016 Hepatology | This work was supported by a Medical Research Council (MRC) UK Development Clinical Scheme award (G0701694); by the Wellcome Trust, the Oxford NIHR/BC, and the U19 grant (ZU13A01002630-06, to C.K. and P.K.); by an MRC CASE studentship (to L.S.). E.B. is funded as an MRC Senior Clinical Scientist and is supported by the Oxford NIHR BRC, the Oxford Martin School, and the Jenner Institute. | Dr. Colloca, Dr. Folgori, Dr. Cortese, and Dr. Nicosia are named inventors on patent applications covering hepatitis virus-vectored vaccines and chimpanzee adenovirus vectors (WO 2006133911 [A3] hepatitis C virus nucleic acid vaccine, WO 2007071091 [A3] chimpanzee adenovirus vaccine carrier, WO 03031588 [A2] hepatitis C virus vaccine). Dr. Hill is a coinventor on patent filings and applications related to heterologous prime-boost immunizations. | NCT01094873, 2008-006127-32) | N/A | 20/12/2020 |
| Kimani D | Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naïve to malaria-endemic populations | 2014 Molecular Therapy | This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), a four and a half year integrated project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP, grant number IP.2008.31100.001). N.I.V. is an employee of the European Vaccine Initiative (EVI). E.V.I. is the coordinator of the EDCTP funded MVVC project (grant number IP.2008.31100.001). E.V.I. supports salaries of the MVVC project in kind. The work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbroc.org/) [A91301 Adult Vaccine], the Wellcome Trust (http://www.wellcome.ac.uk/) [084113/Z/07/Z] and the Medical Research Council. S.H.H. holds a Wellcome Trust research training fellowship (097940/Z/11/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | A.V.S.H. is a named inventor on patent applications on malaria vectored vaccines and immunization regimens. Authors from Okairo are employees of and/or shareholders in Okairo, which is developing vectored vaccines for malaria and other diseases. | N/A | N/A | 16/12/20 |
| Lambe T | Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1 | 2013 Scientific Reports | AVI was funded by a fellowship of the Dr. Saal van Zwabenberg Stichting. Dr. Lambe is supported by the Oxford Martin School. SCC is a Jenner Investigator. | N/A | N/A | N/A | 16/12/20 |
| Longley RJ | Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates | 2015 Scientific Reports | This work has been funded by a grant from the Wellcome Trust (095540/Z/11/Z) with additional funding by the Rhodes Trust and a Nuffield Department of Medicine Studentship to support RIL and EVIMaLR studentship to support AMS. AVSH is a Jenner Institute Investigator; AIS is a James Martin Fellow. CJ is supported by a grant of the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number 242095. | AVSH is a named investigator on US 12/595 574 and UK PCT/GB2008/01262 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimens; RIL, AMS, CJ, SMK, AIS and AVSH are named investigators on filed patent (1310849-9) for novel malaria antigens. | N/A | N/A | 20/12/2020 |
| Longley RJ | Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine | 2017 Infection and Immunity | Funding for manufacture and quality control release and stability studies of Sanaria's PfSPZ challenge was provided by the National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov/) under grant RA4A058375 (Universal Attenuated Malaria Sporozoite Vaccine and Challenge System). The present work was funded by a grant from the Wellcome Trust (grant 095540/Z/11/Z) to A.V.S.H., with additional funding by the Rhodes Trust and a Nuffield Department of Medicine Studentship to support R.J.L. The human CHMI study (VAC049) was supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbroc.org/) [A91301 adult vaccine program] and the Wellcome Trust (grant 084113/Z/07/Z). B.R.H. receives funding from the European Union Seventh Framework Programme FP7/2012-2016 under grant agreement 316655 (VACTRAIN). S.H.H. is a Wellcome Trust Clinical Research Fellow (grant 097940/Z/11/Z). A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow. | A.V.S.H. is a named investigator on novel adenovirus patent applications U.S. 12/595 574 and UK PCT/GB2008/01262, covering malaria vectored vaccines and immunization regimens. R.J.L., A.J.S., and A.V.S.H. are named investigators on patent PCT/GB2014/053077, identifying novel malaria vaccine antigens. | NCT01465048 | N/A | 21/12/2020 |
| López-Camacho C McMahon M | Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors | 2018 Nature Communications | This report is independent research funded by the UK Department of Health and Social Care through Innovate UK "New vaccines for global epidemics: development and manufacture" grant No. 072216 (A.R.-S.), and also funded from an ODA budget (Global Health (ODA), 16/107/05 – Design, development and GMP manufacture of a Zika vaccine) (A.J.H.P. and A.R.-S.). The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. We also acknowledge funding by the UK Medical Research Council (MC_LIU_12014 (A.J.P. and A.K.) and MR/N017552/1 (A.K.)). Juthathip/Mongkolkeapaya is supported by an MRC-Newton Fund grant, Gavin Sreeratan is a Wellcome Trust Senior Investigator. | A.R.-S. and C.L.-C. are co-inventors of the Zika vaccines described in this manuscript, filed by Oxford University Innovation Limited in the International Patent Application No. PCT/GB2017/052220 Zika Vaccine; A.V.S.H. and S.C.G. are co-inventors on a patent application (WO/2012/172277) on the ChAdOx1 viral vectored influenza vaccine which is undertaken in advanced clinical development of viral vectored influenza vaccines. | N/A | N/A | 21/12/2020 |
| Mensah VA | Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge | 2019 Vaccine | The study was funded by an MRC Biomedical Catalyst DFCs DCS award (MR/N006372/1). In addition, this study was partially funded by the NIAD Centers of Excellence for Influenza Research and Surveillance contract (CEIRS, HHSN272201400008C, grant A10946 and grant A142046-01) | The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines with FR being an inventor. SG is an inventor on patents covering ChAdOx1 and MVA-NP + M1, filed and owned by the University of Oxford, and is a co-founder of and consultant to Vaxcitech, a University of Oxford spin-out company which is undertaking advanced clinical development of viral vectored influenza vaccines. | N/A | N/A | 10/12/2020 |
| Mensah VA | Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial | 2017 Frontiers in Immunology | This work was supported by a Strategic Primer grant award from the European and Developing Countries Clinical Trials Partnership (EDCTP, grant number SP.2013.41304.025); with co-funding from Swedish International Development Cooperation Agency (Sida); UK Medical Research Council; Irish Aid, Department of Foreign Affairs and Trade, Ireland; and Bundesministerium für Bildung und Forschung (BMBF), Germany. European Vaccine Initiative (EVI) coordinated the project under phase two of Malaria Vectored Vaccines Consortium (MVVC 2). Additional funding for the Oxford collaborators was provided by the Wellcome Trust and the UK National Institute of Health Research. | The following authors have declared that no conflict of interest exists: VM, SR, EK, AMN, FD, CB, GB, YI, RR, NV, FD, OL, AL, BR, BK, RC, SE, EC, KE, GJ, and MA. AH is a named inventor on patent applications on malaria vectored vaccines and immunization regimens. RC and AIN are employees and/or shareholders in ReiThera, which develops vectored vaccines for malaria and other diseases. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AI declared a past collaboration with four of the authors, OL, NV, FD, and AH, to be the handling Editor. We have the following interests. Adrian V.S. Hill is a named inventor on patent applications and patents on malaria vectored vaccines and immunisation regimes including the following (WO2008/022769, Adenoviral vector encoding malaria antigens; and WO2008/122811 Novel adenovirus vectors). Egeraun Imouhuede and Ines Petersen were employees of EVI at the time of the study, which supports the development and testing of malaria vaccines. Nicola Vebjerg is an employee of EVI and Odile Leroy is executive director of EVI. Authors from ReiThera (formerly Okairo) are employees of and/or shareholders in ReiThera, which is developing vectored vaccines for malaria and other diseases. Alfredo Nicosia was employed by ReiThera (formerly Okairo) at the time of the study. | NCT02083887 | N/A | 21/12/2020 |
| Munster VJ | Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model | 2017 NPJ Vaccines | This study was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), an integrated project funded by EDCTP (grant number IP.2008.31100.001). Co-funding was also provided by the Medical Research Council/UK, the Swedish International Development Cooperation Agency (Sida) and Irish Aid. The work was also supported by the Dakar University Cheikh Anta Diop. | S.C.G. is a co-founder of, consultant to and shareholder in Vaxcitech plc, which is developing a vectored MERS vaccine. Remaining authors declare that they have no competing financial interests. | N/A | N/A | 21/12/2020 |

| | | | | | | | |
|----------------------|--|---|---|--|---|-----|------------|
| Nébié I | Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors | 2014 Clinical and Vaccine Immunology | This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and wasperformed by the Malaria Vectors Vaccines Consortium (MVCC), an integrated project funded by EDCTP (grant numberIP.2008.31.100.001). | N/A | N/A | N/A | 16/12/20 |
| O'Hara GA | Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector | 2012 The Journal of Infectious Diseases | Financial support. This work was supported by an Experimental Medicine grant from the UK Medical Research Council (grant number G0502018) with additional support from the UK National Institute for Health Research Oxford Biomedical Research Centre and the Wellcome Trust. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | NCT00890019 | N/A | | 16/12/20 |
| Ogwang C | Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults | 2015 Science Transitional Medicine | This work was funded by the European and Developing Countries Clinical Trials Partnership, grant number IP.2008.31.100.001, to the Malaria Vectors Vaccines Consortium(MVCC), and coordinated by the European Vaccine Initiative (EVI), P.B. is jointly funded by The U.K. Medical Research Council (MRC) and the U.K. Department for International Development(DfID) under the MRC/DfID Concordat agreement. | A.V.S.H., A.N., and S.G. are listed as inventors on patent filings related to heterologous prime-boost immunization and specific malaria vaccines. E.B.I. was an employee of EVI at the time of this study, which supports the development and testing of malaria vaccines. N.K.V. is an employee of EVI, and D.L. is executive director of EVI. A.N. is an employee of Okavios and consultant for GlaxoSmithKline. The other authors declare no competing interests. | NCT01666925, PACTR.201202000356208 | N/A | 20/12/2020 |
| Ogwang C Payne RO | Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults | 2013 Plos One | This work was performed by the Malaria Vectors Vaccines Consortium (MVCC), a four year integrated project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP). The work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbrg.org/) (A91301 Adult Vaccine), the Wellcome Trust (http://www.wellcome.ac.uk/) (084113Z/207/2) and the Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | Competing interests:AM is a named inventor on the following patent applications on malaria vectored vaccines and immunization regimens (WO2008/122769 Adenoviral vector encoding malaria antigen; and WO 2008/122811 Novel adenovirus vectors). Authors from Okavio's are employees of and/or shareholders in Okavio's, which is developing vectored vaccines for malaria and other diseases. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. | Pactr.org PACTR201002000171828 Pactr.org PACTR201008000221638 ClinicalTrials.gov NCT01373879;ClinicalTrials.gov NCT01373830 | N/A | 16/12/20 |
| Payne RO | Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies | 2017 JCI Insight | This work was supported by a UK Medical Research Council (MRC) grant (number G1100086). The study was also supported in part by UK National Institute of Health Research (NIHR) infrastructure through the NIHR Oxford Biomedical Research Centre and the Wellcome Trust (084113Z/07/2). DL was supported by the Rhodes Trust. TAB holds a Wellcome Trust Research Training Fellowship (108734Z/15/2). SGC was a PhD student supported by the European Malaria Vaccine Development Association, a European Commission Framework Programme 6-funded consortium (grant LSHP-CT-2007-037506). TDO is sup-ported by the Wellcome Trust (WT 098051). JSM is supported by an NIHRMRC Practitioner Fellowship (number 10418020). AVSH and SID are Jenner Investigators. SID is a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow (grant number 106917Z/15/2). | S.C. de Cassan, M.K. Higgins, A.V.S. Hill, and S.J. Draper are named inventors on patent applications (patent nos. GB1413530.5, GB1016471.3, and WO/2008/122811) covering malaria vaccines and immunization regimens. A. Nicosia was an employee of and shareholder in Okavios (since acquired by GlaxoSmithKline), which is developing vectored vaccines for a number of diseases. T. Jørgensen and W. A. de Jongh are employees of, and W.A. de Jongh is a shareholder in, Express2Bio Biotechnologies, which has developed and is marketing the ExpreS2 cell expression platform. C.E. Chitnis is a named inventor on a patent covering PvDBP_RII (patent no. WO/1996/040766). | NCT01816113 | N/A | 21/12/2020 |
| Pearson FE | Dry-coated live viral vector vaccines delivered by nanopatch microneedles retain long-term thermostability and induce transgene-specific T cell responses in mice | 2013 Plos One | This work was supported by funding from the European Union Seventh Framework Programme (FP7/2007-2013) under the grant agreement for MultiMaMax (number 305282). The study was also supported in part by UK NIHR infrastructure through the NIHR Oxford Biomedical Research Centre, the MAVARE-CA program funded by Danida (the Consultative Committee for Development Research, Denmark), and the Wellcome Trust (grant numbers 084113Z/07/2 and 206194). The GIA work was supported by the United States Agency for International Development (USAID) and the Intramural Program of the NIH, National Institute of Allergy and Infectious Diseases. DQWA holds a UK MRC ICASE PhD Studentship (MR/K017632/1); JSM is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (10418020); ADD held a Wellcome Trust Training Fellowship for Clinicians in Basic Sciences (088455Z/09/2); SB, AVSH, and SID are Jenner investigators; and SID is a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow (106917Z/15/2). | S.J. Draper is a named inventor on patent applications relating to RHS and/or other malaria vaccines and immunization regimens; is a cofounder of, shareholder in, and consultant for SpyBiotech; and declares research funding support from Pfizer and GSK BioPharm. A.D. Douglas, G.J. Wright, and A.V.S. Hill are named inventors on patent applications relating to RHS and/or other malaria vaccines and immunization regimens. L. Siani and S. Di Marco are employees of RetiThera (formerly Okavios), which is currently developing vectored vaccines for a number of diseases. J. Vekemans was an employee of GSK, which has acquired the ChAd63 vector from Okavios. R. Ashfield is a director of Duocents and holds shares in the company, which is developing a therapy for autoimmune disease. A.M. Minassian has an immediate family member who is an inventor on patents relating to RHS and/or other malaria vaccines and immunization regimens and who is a cofounder of, shareholder in, and consultant for SpyBiotech. S. Biswas is a cofounder and CEO of, and shareholder in, Spybiotech and is a contributor to a patent application relating to multimerisation technology. J. Jin is a cofounder of and shareholder in SpyBiotech. Competing interests:Authors MLC, GJPF, XC and MAFK are either inventors or contributors to a patent filings related to the NanopatchTM technology, that is now licensed to Vaxxas Pty Ltd. These are detailed in Supporting Information - Table S2. Authors MLC, SRY, GJPF and MAFK have employment with Vaxxas. MAFKs a member of the Vaxxas board. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. | NCT02181088 | N/A | 21/12/2020 |
| Pearson FE | Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine | 2015 Vaccine | This study was funded by Enterprise Ireland (CFTD07/117,http://www.enterprise-ireland.com), Science Foundation Ireland (NAP156andNAP170, www.sfi.ie) and the Medical Research Council (United Kingdom (G0600311, www.mrc.ac.uk) and by the Bill andMelinda Gates Foundation (003436, www.gatesfoundation.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | None | N/A | N/A | 20/12/2020 |
| Pérez de Val B | Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS02B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP | 2013 Plos One | The study was funded by the European Community's 7th Framework Programme (FP7-KBBE-2007-1-3-04- TB-STEP project under grant agreement212414). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | N/A | N/A | N/A | 16/12/20 |
| Rampling T | Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP | 2016 The Journal of Infectious Diseases | This work was supported by the PATH Malaria Vaccine Initiative and by the United Kingdom NIHR, through the NIHR Oxford Biomedical Research Centre, the Southampton NIHR Wellcome Trust Clinical Research Facility, and the Imperial College NIHR Wellcome Trust Clinical Research Facility. | This work was supported by the PATH Malaria Vaccine Initiative and patents relating to malaria vectored vaccines and immunization regimens. D. M. M. L., and R. W. B. are employees of GSK, which is developing vaccines for malaria and other diseases. S. N. F. acts on behalf of the University of Southampton/University Hospital Southampton/National Health Service Foundation trust as chief and principal investigator for clinical trials sponsored by vaccine manufacturers, including GSK, but receives no personal payments for the work. | NCT01883609 | N/A | 20/12/2020 |
| Rampling T | Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP | 2018 Nature partner journals | This work was funded primarily by the PATH Malaria Vaccine Initiative (MVVI). In addition, the work was supported by the United Kingdom National Institute of Health Research (NIHR) infrastructure, through the NIHR Oxford Biomedical Research Centre, the Southampton NIHR Wellcome Trust Clinical Research Facility, and the Imperial College NIHR Wellcome Trust Clinical Research Facility; this article/paper/report presents independent research funded by PATH MVVI and supported by the NIHR CRF and BRC at Imperial College Healthcare NHS Trust. Views expressed are those of the author(s) and not necessarily those of PATH MVVI, the NIHR, or the Department of Health. | A.V.S.H. and S.C.G. are named inventors on patent applications and patents relating to malaria vectored vaccines and immunization regimens. D. M. M. L., and R. W. B. are employees of GSK, which is developing vaccines for malaria and other diseases. S.N.F. acts on behalf of the University of Southampton/University Hospital Southampton NHS Foundation trust as chief and principal investigator for clinical trials Sponsored by vaccine manufacturers including GSK, but receives no personal payments for the work. The other authors declare no competing interests. | NCT02252640 | N/A | 18/12/20 |
| Reyes-Sandoval A | Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses | 2010 Human Vaccines | Work in the Oxford malaria vaccine program is supported by the Wellcome Trust, the UK Medical Research Council, the UK National Institute for Health Research through the Oxford Biomedical Research Centre, the European Commission, the Gates Foundation through a Grand Challenges in Global Health award from the Foundation for NIH, the European Malaria Vaccine Initiative, the Jenner Vaccine Foundation and the European and Developing Countries Clinical Trials Partnership. We thank the Jenner Institute's vector core facility for providing the viral-vectored vaccines and Dr Helen McShane for providing the ad-enoviral and MVA vectors expressing antigen BSA. We are also grateful to Andrew Williams for providing the P. berghei parasites and the NIH tetramer facility (MHC tetramer core facility, Emory University Vaccine Center, Atlanta, GA) for preparing the PB9 tetramer. The transgenic parasites were kindly provided by Dr Oliver Billker from Wellcome Trust Sanger Institute, Hinxton, UK. This work was funded by Wellcome Trust Principal Research Fellowship award; Grant Number: 076438; The National Institute for Health Research Oxford Biomedical Research Centre Program and Grand Challenges in Global Health. A.R.-S. is a Scientific Leadership Fellow of the Nuffield Department of Medicine and a Wellcome Trust Fellow. C.S.R. is supported by Oxford Biomedical Research Center, The Oxford Martin School and Meningitis UK. | N/A | N/A | N/A | 10/12/2020 |
| Reyes-Sandoval A | Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity | The American Society of Gene & Cell 2010 Therapy | The work was supported by a Wellcome Trust Principal Research Fellowship award grant number 076438 to A.V.S.H. | N/A | N/A | N/A | 16/12/20 |
| Reyes-Sandoval A | Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei | 2008 European Journal of Immunology | | N/A | N/A | N/A | 16/12/20 |

| | | | | | | | |
|-------------------------|---|---|---|--|--------------------------|-----|------------|
| Rollier CS | | | This work was funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative of the Gates Foundation, with additional support from the Wellcome Trust. Non-human primate studies were supported by National Center for Research Resources (NCRR) grant # P51 RR000167, and were conducted at a facility constructed with support from grants RR15459 and RR020141. The authors wish to acknowledge the expert contribution of Dr Matthew G. Cottingham, and the expert help provided by the Animal Services Unit, and the Immunology Services Unit of the Wisconsin National Primate Research Center. In particular D. Watkins and E. Rakasz. CR is supported by the NIHR Biomedical Research Centre, Oxford. CR, SGC and AVSH are Jenner Institute Investigators and AVSH is a Wellcome Trust and NIHR Senior Investigator. The funding sources had no involvement in study design; collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication. | A.V.S.H. and S.G.C. are names as co-inventors on patents related to recombinant viral vectors for malaria and other indications. | N/A | N/A | 18/12/20 |
| Salman AM | Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule | 2020 Nature | he work was funded by a Wellcome Trust Career Development Fellowship award, grant number 097395/Z11/Z, to A.R.-S., who is also a Jenner Investigator and an Oxford Martin Fellow. Funding was also provided by the Medical Research Council, through a DPGS grant (MR/N029008/1) to A.R.-S. Ahmed M. Salman was funded by EVMalaria's Program Funding (FP7/2007-2013) under grant agreement N° 242095. Adrian Hill is supported by a Wellcome Trust grant number 095540/Z11/Z and is a Jenner Investigator and an Oxford Martin Fellow. | N/A | N/A | N/A | 21/12/2020 |
| Sebastian S | Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models A Multi-Fibrosis Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector | 2017 Scientific Reports 2020 MDPI | This research was funded by Innovate UK (Novel multivalent vaccines against haemorrhagic fevers, 971510) and MRC (Confidence in Concept CIC 2015-16, MC_PC_15040, Liverpool School of Tropical Medicine). This work was supported by the European Malaria Vaccine Development Association (EMVDA), a European Commission FP6-funded consortium (http://www.emvda.org/) (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordorc.org/) (A91301 Adult Vaccine); and the Wellcome Trust (http://www.wellcome.ac.uk/) (084113/Z/07/Z). The GIA work was supported by the PATH Malaria Vaccine Initiative (MV); http://www.malaria-vaccine.org/) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov/Pages/default.aspx). CIAD holds a Wellcome Trust Research Training Fellowship (BTEI); S.C.G., A.V.S.H., and S.J.D. are Jenner investigators. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship (45488/Z/05); and S.J.D. is a UK Medical Research Council Career Development Fellow (G1000527). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | N/A | N/A | N/A | 18/12/20 |
| Sheehy SH | Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors | 2012 Plos One | This work was supported by the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK Medical Research Council (grant no. G0700735); the UK National Institute of Health Research through the Oxford Biomedical Research Centre (A91301 Adult Vaccine); and the Southampton NIHR Wellcome Trust Clinical Research Facility, the Wellcome Trust (084113/Z/07/Z); and EVMalaria, an European Commission FP7-funded programme (grant agreement no. 242095). The growth inhibitory activity work was supported by the PATH Malaria Vaccine Initiative and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. S.C.G., A.V.S.H., and S.J.D. are Jenner investigators. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship (45488/Z/05); C.J.A.D. holds a Wellcome Trust Research Training Fellowship (094449/Z10/Z); and S.J.D. is a UK Medical Research Council Career Development Fellow (G1000527). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | Competing Interests: AIS, MDJD, SGC, AVSH and SID are named inventors on US 12/595 574 and UK PCT/GB2008/01262, US 12/595 351 and UK PCT/GB2008/01271 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimens. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. Authors from Okairo's are employees of and/or shareholders in Okairo's, which is developing vectored vaccines for malaria and other diseases. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. | NCT01095055 | N/A | 16/12/20 |
| Sheehy SH | ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans | The American Society of Gene & Cell 2012 Therapy | This work was supported by the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through Oxford Biomedical Research Centre (A91301 Adult Vaccine) and the Wellcome Trust (084113/Z/07/Z). The GIA work was supported by the PATH Malaria Vaccine Initiative (MV) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. S.C.G., A.V.S.H., and S.J.D. are Jenner investigators. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship (45488/Z/05); C.J.A.D. holds a Wellcome Trust Research Training Fellowship (094449/Z10/Z); and S.J.D. is a UK Medical Research Council Career Development Fellow (G1000527). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | N/A | N/A | N/A | 16/12/20 |
| Sheehy SH | Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors | 2011 The Journal of Immunology | This work was supported by the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through Oxford Biomedical Research Centre (A91301 Adult Vaccine) and the Wellcome Trust (084113/Z/07/Z). The GIA work was supported by the PATH Malaria Vaccine Initiative (MV) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. S.C.G., A.V.S.H., and S.J.D. are Jenner investigators. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship (45488/Z/05); and S.J.D. is a MRC Career Development Fellow (G1000157). A.R.W., S.C.G., A.V.S.H., and S.J.D. are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. Authors from Okairo's are employees of and/or shareholders in Okairo's which is developing vectored vaccines for malaria and other diseases. | N/A | N/A | N/A | 16/12/20 |
| Spencer AJ Stedman A | Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class II invariant chain | 2014 Plos One | This work has been funded by grants from the Foundation for the National Institute of Health through the Grand Challenges in Global Health Initiative (HL050080) with additional funding from the Wellcome Trust (095540/Z11/Z). Non-human primate studies were supported by National Center for Research Resources (NCRR) grant # P51 RR000167, and was conducted at a facility constructed with support from grants RR15459 and RR020141. The funding bodies did not have a role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. Co-authors S. Capone, S. Colloca, AF, RC and AN are employees of Okairo's. Okairo's provided support in the form of salaries for the authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the 'author contributions' section. | AVSH is a named inventor on WO/2008/122811-Adenoviral vectors encoding a pathogen or tumour antigen and WO/2008/122769-Adenoviral vector encoding malaria antigen, S. Colloca, AF, RC, and AN are named inventors on patent application WO 2005071093 (A3)-Chimpanzee adenovirus vaccine carriers. Authors from Okairo's were employees of and/or share holders in Okairo's, this does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. | N/A | N/A | 16/12/20 |
| Svitek N | Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats | 2019 Nature partner journals | This study was funded by the UK Department of Health and Social Care (UK DHSC, Project 16/107/03). G.M.W. is supported by an Oak Foundation fellowship and a Wellcome Trust grant 203077_2_16_20. S.C.G., B.C. and A.V.S.H. are Jenner investigators. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this publication are those of the authors and do not necessarily reflect those of the UKDHSC. We thank Dr. Connie Schmaljohn (USAMRIID, Fort Detrick, MD) for providing the 4-D4 antibody. This paper is published with the permission of the Pirbright Institute and the Director of the Kenya Medical Research Institute. | S.C.G. and A.V.S.H. are co-founders of, consultants to and shareholders in Vaccitech Ltd., which is developing ChAdOx1-vectored vaccines. The remaining authors declare no competing interests. | N/A | N/A | 18/12/20 |
| Swadling L | An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8+ central memory T cells and confers partial protection against a lethal challenge | 2018 Nature partner journals | This work was funded by the Bill and Melinda Gates Foundation (BMGF) and the Department for International Development (DFID) of the United Kingdom (OPPI078793), the Norman Borlaug Commemorative Research Initiative, an initiative between the Feed the Future program of United States Agency for International Development (USAID), USA and United States Department of Agriculture (USDA)-Agricultural Research Service, USA (58-5348-2-117f) and through funding from the CGIAR Research Program on Livestock and Fish (CRP 3.7) | N/A | N/A | N/A | 18/12/20 |
| Swadling L | A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory | 2014 Science Translational Medicine | Funding Supported by the Medical Research Council (MRC) UK and the European Union (Framework V; HEPACVAC) for funding the study and the manufacture of MVA-Nsmut through an MRC UK DCS (Developmental Clinical Studies) award. E.B. is supported by the MRC as a Senior Clinical Fellow, the Oxford Martin Schools, and National Institute for Health Research Oxford Biomedical Research Centre. L. Swadling is supported by an MRC CASE studentship. Supported by the Medical Research Council (MRC) UK and the European Union (Framework V; HEPACVAC) for funding the study and the manufacture of MVA-Nsmut through an MRC UK DCS (Developmental Clinical Studies) award (G0701694). Christabel Kelly and Paul Klenerman are supported by the Wellcome Trust, the Oxford NIHR BRC and the US3 grant 2U19AI082630-06). Leo Swadling is supported by an MRC CASE studentship. Eleanor Barnes is funded as an MRC Senior Clinical Fellow, and is supported by the Oxford NIHR BRC, the Oxford Martin School and the Jenner Institute. | Competing interests: S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee adenovirus vectors (WO 2006133511 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093(A3) chimpanzee adenovirus vaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine). P.K. has acted as a consultant to Tibotec and Pfizer on antiviral therapy. The other authors declare that they have no competing interests. | N/A | N/A | 16/12/20 |
| Swadling L | Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 2b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial | 2016 Vaccines | This study was funded by a Wellcome Trust Strategic Translation Award, with funding contributions from the Medical Research Council UK, and the Department for International Development UK supported the primary vaccination of 80 Malian participants with ChAd3-EBO-Z. A Wellcome Trust Enhancement Award funded the boosting of 52 Malians with MVA-BN-Filo or saline. Funding for priming immunisation of the Malian participants with the ChAd3-EBO-Z vaccine and for data management was provided by the National Cancer Institute, the National Laboratory for Cancer Research, Federal Funds from the National Institute of Allergy and Infectious Diseases, and a contract (number HHSN26120080001E) awarded to Leidos Biomedical Research. The US trial was funded by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, through a contract to the EMMES Corporation. | Stefano Colloca, Antonella Folgori, Riccardo Cortese and Alfredo Nicotri are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee adenovirus vectors (WO 2006133511 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirus vaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine). Adrian Hill is a co-inventor on patent filings and applications related to heterologous prime-boost immunisations. | NCT01296451 | N/A | 20/12/2020 |
| Tapia MD | | 2016 The Lancet Infectious Diseases | This study was funded by the Wellcome Trust Strategic Translation Award, with funding contributions from the Medical Research Council UK, and the Department for International Development UK supported the primary vaccination of 80 Malian participants with ChAd3-EBO-Z. A Wellcome Trust Enhancement Award funded the boosting of 52 Malians with MVA-BN-Filo or saline. Funding for priming immunisation of the Malian participants with the ChAd3-EBO-Z vaccine and for data management was provided by the National Cancer Institute, the National Laboratory for Cancer Research, Federal Funds from the National Institute of Allergy and Infectious Diseases, and a contract (number HHSN26120080001E) awarded to Leidos Biomedical Research. The US trial was funded by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, through a contract to the EMMES Corporation. | FR, IDR, and WRB are employees of GlaxoSmithKline and manufacture non-replicating chimpanzee adenovirus 3-based vaccines. NS is a named inventor on patents related to ChAd3-EBO-Z. AVSH is named as an inventor on patents using heterologous prime boost immunisation with viral vectors, such as those assessed in this report. MML serves as a member of the Scientific Advisory Working Group to the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, and of the Vaccine Research Center Board of Scientific Counselors. | NCT02231866, NCT02267109 | N/A | 20/12/2020 |

| | | | | | | |
|------------------------------------|---|---|---|--|---------------------------------------|---------------------------------------|
| | | | This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), a 5-year integrated project (Grant number IP 2008-31100-001). The European vaccine initiative (EVI) was the coordinator of the EDCTP-funded MVVC project. Co-funding was also provided by the Swedish International Development Cooperation Agency (SIDA), the Austrian Federal Ministry of Science and Research, and Irish Aid. Additional support for the Oxford clinical trials team was provided by the UK NIHR through the Oxford Biomedical Research Centre | : AVSH is a named inventor on patent applications and issued patents relating to malaria vectored vaccines and immunization regimes. This does not alter the author's adherence to all the PLOS ONE policies on sharing data and materials. | NCT01635647; PACTR20120800040131; N/A | 21/12/2020 |
| Tiono AB | First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children | 2018 Plos One | | | | |
| Tuthill M. | Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA ST4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer | 2020 Annals of Oncology (Abstracts) | European Union Seventh Framework Programme under grant Agreement No. 602705 (Project IMPROVE) and VacciTech Ltd. | | NCT03815942 | 18/12/20 |
| Utrilla-Trigo S | Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus | 2020 MDPI | This work was supported by grants AGL2017-82570-R from the Spanish Ministry of Science and EU Horizon 2020 Program (European Commission Grant Agreement No. 727393-PALE-BL). SUT was a recipient of a predoctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Centro de Investigación en Sanidad Animal (program FPI-SGIT-201). | N/A | N/A | 18/12/20 |
| van Doremalen N van Doremalen N | A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters | 2020 Science Advances 2019 PLOS | This work was supported by the Intramural Research Program of the National Institute of Health and Infectious Diseases (NIH), NIH (1Z1AA001179-01) and the Department of Health and Social Care using UK Aid funding managed by the NIHR.S.C.G. is a Jenner investigator. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. This work was supported by the Intramural Research Program of the National Institute of Health and Infectious Diseases (NIH), National Institutes of Health (NIH), TAB (issuported by the Medical Research Council (MR/L009528/1). SCG is a Jenner investigator. The sponsors did not play a role in study design. | S.C.G. is a board member of VacciTech and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines. The other authors declare that they have no competing interests. I have read the journal's policy and the authors of this manuscript have the following competing interests: SCG is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines. The remaining authors declare no conflict of interest. | N/A N/A | 18/12/20 18/12/20 |
| van Doremalen N Venkatraman N | ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques | 2020 Nature | This work was supported by the Intramural Research Program of the National Institute of Health and Infectious Diseases (NIH), National Institutes of Health (NIH) (1Z1AA001179-01) and the Department of Health and Social Care using UK Aid funding managed by the NIHR. This work was supported by the Wellcome Trust, the UK Medical Research Council, the UK Department for International Development, and the UK NIHR Oxford Biomedical Research Centre. The Good Manufacturing Practice biomanufacture of MVA-EBO-Z and the UK clinical trial was supported by an Enhancement Award to a Wellcome Trust Strategic Award (to A. V. S. H. as principal investigator) co-funded by the Medical Research Council, the Department for International Development, and the European and Developing Countries Clinical Trials Partnership (grant number 106252/21/AA), with additional support from the NIHR Oxford Biomedical Research Centre. The Senegal trial was largely funded by a European Commission Horizon 2020 program award EboVac (www.ebovac.eu; grant agreement 666085), which provided additional resources for the MVA-EBO-Z biomanufacture. This study was also supported by GlaxoSmithKline Biologicals SA. | S.C.G. is a board member of VacciTech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and VacciTech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor VacciTech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. The other authors declare no competing interests. | N/A | AZ in competing interests 18/12/20 |
| Walker AS Wang C | Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines | 2019 The Journal of Infectious Diseases 2015 American Journal of Tropical Medicine and Hygiene | Andrew S. Walker, José Lourenço and Sunetra Gupta are funded by the European Research Council (ERC Advanced Grant—Diversity). AVSH is a Jenner Investigator and Wellcome Trust and NIHR Senior Investigator. | F. R. and W. R. B. are employees of GSK and own restricted shares of the company. S. C. G., K. E., and A. V. S. H. are named inventors on patents relating to viral vector vaccines for malaria and other diseases. F. R. and W. R. B. are employees of GSK, which is developing vectored vaccines for Ebola and other diseases. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. | NCT02451891; NCT02485912 | 18/12/20 |
| Warimwe GM | A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis | 2018 Plos Neglected Tropical Diseases | This work has been supported by the UK Medical Research Council including Confidence in Concept (grants MC_PC_13073 and MR/P017339/1). SID, AVSH and ADD are Jenner investigators; SID is also a later Institute Research Prize Fellow and a Wellcome Trust Senior Fellow (grant 106917/2/15/Z). ADD is supported by the Wellcome Trust (grant 202147/2/16/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was conducted with the support from the University of Oxford, a Wellcome Trust fellowship to GMW (WT098635) and grant from the Bill & Melinda Gates Foundation through the Grand Challenges Exploration Initiative to GMW (OPP106893). B.C., S.C.G. and A.V.S.H. are Jenner investigators. | N/A | N/A | 20/12/2020 |
| Warimwe GM Lorenzo Yoshida K | Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever Immunogenicity and efficacy of a chimpanzee adenovirus vectored Rift Valley fever vaccine in mice | 2016 Scientific Reports 2013 Virology Journal | This work was supported by a Wellcome Trust fellowship in Public Health and Tropical Medicine to GMW (grant no. 098635/B/12/Z) and by Spanish Ministry of Science grant (no. AGL2011-22485) to AB. ELG is a recipient of a pre-doctoral fellowship program from the Spanish Ministry of Sci-ence. SCG and AVSH are Jenner investigators. | AVSH and ADD are named inventors on a patent application relating to the development of the ChAdOx2 vector. AVSH and SID are named inventors on a patent relating to the use of the intron-containing promoter used in ChAdOx2 RabG. The University of Oxford and the Wistar Institute have entered into a partnership to share any future revenue from development of the ChAdOx2 RabG vaccine. | N/A N/A | 21/12/2020 16/12/20 |
| | Adenovirus prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model | 2018 Scientific Reports | This work was supported, in part, by a Grant-in-Aid for Young Scientists (B) (JSPS KAKENHI grant number 2680278), a grant from the Ohama Health Foundation, and Cooperative Research Grants from NEXKEN, 2034 (grant number 26-6) and 2015 (grant number 27-5) to M.L.; by Grants-in-Aid for Scientific Research (B) (JSPS KAKENHI grant numbers 2130126 and 25305007) and a Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI grant number 24659460) to S.Y.; and by the UK Medical Research Council (award number MR/N02274/1) to A.M.B. | The authors have read the journal's policy and declare the following conflicts of interest: S.Y. and A.H. are named inventors on filed patents related to immunization with the B.D.E.S. (WO/2007/091624) and ChAd63 (WO/2008/022769) anti-malaria vaccines, respectively. Neither of these products has been commercialized. None of the authors have undertaken any consultancies relevant to this study. These conflicts of interest do not alter the authors' adherence to all the policies of Scientific Reports on sharing data and materials, as detailed online in the guide for authors. | N/A | 21/12/2020 |

| Award number | Funder name | Awardee (to whom was the grant?) | Date | Amount | Exchange rate | Amount in GBP | Relevant publications (author and date) | Direct citation from articles |
|---------------------|---|----------------------------------|-----------------|----------------------|---------------|-----------------|---|---------------------------------|
| - | AIDS Vaccine Initiative | - | - | - | - | - | Borthwick et al (2014) | The work was supported by |
| - | Austrian Federal Ministry of Science and | - | - | - | - | - | Tiono (2018) | This work was supported by a |
| BBS/E/I/00001373 | BBRSC | <u>Bryan Charleston</u> | Jan 09 - Jan 13 | £790,209 | | £ 790,209.00 | Dicks et al (2015 - 2) | This work has been funded by |
| BB/H010556/1 | BBSRC | <u>Tim Bull</u> | Mar 10 - May 13 | £351,371 | | £ 351,371.00 | Bull et al (2014) | This work was supported by B |
| BB/H010718/1 | BBSRC | <u>Jayne Hope</u> | Sep 11 - Aug 13 | £235,928 | | £ 235,928.00 | Bull et al (2014) | This work was supported by B |
| - | BBSRC | Hope J | - | - | - | - | Bull et al (2014) | This work was supported by B |
| - | BBSRC | McGuines I | - | - | - | - | Bull et al (2014) | This work was supported by B |
| LDAD_P15820 | BBSRC | - | - | - | - | - | Goodman et al (2011) | This work was supported prim |
| LDAD_P15820 | BBSRC | - | - | - | - | - | Goodman et al (2011) | This work was supported prim |
| OPP1096893 | Bill & Melinda Gates Foundation | <u>Warimwe GM</u> | - | - | - | - | Dulal et al (2016) | This study was conducted with |
| OPP1096893 | Bill & Melinda Gates Foundation | Warimwe GM | - | - | - | - | Warimwe et al (2016) | This work was conducted with |
| OPP1078791 | Bill and Melinda Gate Foundation | Research Institute | | Oct-13 \$ 10,999,924 | 0.72 | £ 7,919,945.28 | Svitek (2018) | This work was funded by the f |
| OPP1215550 | Bill and Melinda Gates Foundation | The Pirbright Institute | | Nov-19 \$ 5,530,900 | 0.72 | £ 3,982,248.00 | S Graham (2020) | and the Bill and Melinda Gate |
| - | 3436 Bill and Melinda Gates Foundation | - | - | - | - | - | Pearson et al (2013) | This work has been supported |
| - | Biotechnology and Biological Sciences R | - | - | - | - | - | Boyd et al (2013) | The Biotechnology and Biolog |
| - | Bundesministerium für Bildung und Fors | - | - | - | - | - | Mensah (2017) | This work was supported by a |
| - | Cancer Research | Malinauskas T | - | - | - | - | Bauza et al (2014) | The work was funded by a We |
| - | Cancer Research | Jones EY | - | - | - | - | Bauza et al (2014) | The work was funded by a We |
| - | CAPE | Atcheson E | - | - | - | - | Atcheson (2018) | The work was funded by a We |
| CRP 3.7 | CGIAR Research Program on Livestock a | - | - | - | - | - | Svitek (2018) | This work was funded by the f |
| - | Coalition for Epidemic Preparedness Inn | - | - | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| finance code 001 | Coordenacao de Aperfeicoamento de Pe | Folegatti P.M | - | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| finance code 001 | Coordenacao de Aperfeicoamento de Pe | - | - | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| - | Dakar University Cheikh Anta Diop | - | - | - | - | - | Mensah et al (2016) | This study was supported by a |
| - | Danida | - | - | - | - | - | Payne et al (2017) | This work was supported by ft |
| - | Department for Business, Energy and Industrial Strategy | - | - | £65,500,000.00 | | £ 65,500,000.00 | https://www.imperial.ac.uk/news/197573/covid-19-vacc | |
| - | Department for Business, Energy and Industrial Strategy | - | - | £20,000,000.00 | | £ 20,000,000.00 | https://www.imperial.ac.uk/news/197017/imperial-covi | |
| - | Department for International Developm | - | - | - | - | - | Bowyer (2018) | The clinical trial was supporte |
| - | Department for International Developm | - | - | - | - | - | Venkatraman N (2019) | This work was supported |
| - | Department of Biotechnology, Governm | Chauhan VS | - | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student sup |
| - | Department of Biotechnology, Governm | Chitnis CE | - | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student sup |
| - | Department of Foreign Affairs and Trade | - | - | - | - | - | Mensah (2017) | This work was supported by a |
| - | DFID | - | - | - | - | - | Tapia et al (2016) | This study was funded by a W |
| - | DFID | - | - | - | - | - | Ewer et al (2016) | Supported by the Wellcome T |
| - | Division of Intramural Research | - | - | - | - | - | Forbes et al (2012) | This work was funded by the \ |
| - | Dr. Saal van Zwanenberg Stichting | van Laarhoven A | - | - | - | - | Lambe et al (2013) | AvL was funded by a fellowsh |
| IP.2008.31100.00 | EDCTP | - | - | - | - | - | Kimani et al (2014) | This work was supported by |
| IP.2008.31100.001 | EDCTP | - | - | - | - | - | Afolabi et al (2016) | Trials Partnership (EDCTP) anc |
| IP.2008.31100.001 | EDCTP | - | - | - | - | - | Mensah et al (2016) | This study was supported by a |
| IP.2008.31100.001 | EDCTP | - | - | - | - | - | Nébié et al (2014) | This work was supported by a |
| - | EMVDA | Dicks MDJ | - | - | - | - | Dicks et al (2012) | This work has been funded by |
| - | EMVDA | Dicks MDJ | - | - | - | - | Dicks et al (2015 - 2) | This work has been funded by |
| - | EMVDA | - | - | - | - | - | Forbes et al (2012) | This work was funded by the \ |
| LSHP-CT-2007-03750 | EMVDA | - | - | - | - | - | Biswas et al (2014) | This work was supported by t |
| LSHP-CT-2007-037506 | EMVDA | - | - | - | - | - | Sheehy et al (2011) | This work was supported by t |
| LSHP-CT-2007-037506 | EMVDA | - | - | - | - | - | Sheehy et al (2012 - 2) | This work was supported by t |
| LSHP-CT-2007-037506 | EMVDA | - | - | - | - | - | Sheehy et al (2012) | This work was supported by |
| LSHP-CT- | | | | | | | | |
| 2007-037506 | EMVDA | - | - | - | - | - | Hodgson et al (2014) | This work was supported by t |
| | EMVDA | - | - | - | - | - | Draper et al (2011) | SB was funded by MalParTrai |

| | | | | | | | |
|------------------------|---|--|-----------------|----------------|----------------------|-------------------------|---|
| EP/R013756/1 | Engineering and Physical Sciences Research Council | Tarit K Mukhopadhyay | Apr 18 - Sep 21 | £6,968,179 | £ 6,968,179.00 | Folegatti P.M.(2020) | UK Department of Health and |
| CFTD07/117 | Enterprise Ireland | - | - | - | - | Pearson et al (2015) | This study was funded by Enterprise Ireland |
| CFTD07/117 | Enterprise Ireland | - | - | - | - | Carey et al (2013) | This work was supported by Enterprise Ireland |
| - | EU HEPACIVAC | - | - | - | - | Swadling (2016) | Supported by the Medical Research Council |
| - | European and Developing Countries Clinical Trials Partnership | - | - | - | - | Bowyer G (2020) | The Oxford clinical trial was supported by the Wellcome Trust |
| - | European and Developing Countries Clinical Trials Partnership | - | - | - | - | Reyes-Sandoval (2010) | Work in the Oxford malaria vaccine development programme |
| - | European and Developing Countries Clinical Trials Partnership | - | - | - | - | Bowyer (2018) | The clinical trial was supported by the Wellcome Trust |
| - | European and Developing Countries Clinical Trials Partnership | - | - | - | - | Venkatraman N (2019) | This work was supported by the Wellcome Trust |
| IP.2008.31100.001 | European and Developing Countries Clinical Trials Partnership | - | - | - | - | Ogwang et al (2015) | This work was funded by the Wellcome Trust |
| SP.2011.41304.025 | European and Developing Countries Clinical Trials Partnership | - | - | - | - | Mensah (2017) | This work was supported by the Wellcome Trust |
| IP.2008.31100.001 | European and Developing Countries Clinical Trials Partnership | - | - | - | - | Tiono (2018) | This work was supported by the Wellcome Trust |
| 666085 | European Commission | GLAXOSMITHKLINE BIOLOGICALS SA | 07-Oct-14 | € 15,153,216 | 0.87 € 13,183,297.92 | Venkatraman N (2019) | This work was supported by the Wellcome Trust |
| 666085 | European Commission | GLAXOSMITHKLINE BIOLOGICALS SA | 07-Oct-14 | € 15,153,216 | 0.87 € 13,183,297.92 | Bowyer G (2020) | The Oxford clinical trial was supported by the Wellcome Trust |
| 242095 | European Commission | Salman AM | 01-Oct-09 | € 12,000,000 | 0.87 € 10,440,000.00 | Atcheson (2018) | The work was funded by the Wellcome Trust |
| 727393-PALE-Blue | European Commission | THE UNIVERSITY OF NOTTINGHAM | 01-Jun-17 | € 6,039,301.50 | 0.87 € 5,254,192.31 | Utrilla-Trigo S (2020) | This work was supported by the Wellcome Trust |
| 602705 | European Commission | - | - | € 6,000,000 | 0.87 € 5,220,000.00 | Cappuccini F (2020) | The VANCE clinical trial was supported by the Wellcome Trust |
| 602705 | European Commission | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD | 01-Apr-14 | € 6,000,000 | 0.87 € 5,220,000.00 | Tuthill M. (2020) | European Union Seventh Framework Programme |
| 316655 | European Commission | Halbroth BR | 01-Nov-12 | € 3,060,467.67 | 0.87 € 2,662,606.87 | Halbroth (2018) | BRH received funding from the Wellcome Trust |
| 316655 | European Commission | Halbroth BR | - | - | - | Gola (2018) | A.G. is funded by the Wellcome Trust |
| - | European Commission | - | - | - | - | Reyes-Sandoval (2010) | Work in the Oxford malaria vaccine development programme |
| IC18-CT95-0019 | European Commission | Fellowship to author to J.S. | - | - | - | Gilbert et al (2002) | Wellcome Trust and the European Union |
| 212414 | European Community's 7th Framework Programme | F UNIVERSIDAD COMPLUTENS | 01-Oct-08 | € 2,894,759 | 0.87 € 2,518,440.33 | Pérez et al (2013) | The study was funded by the Wellcome Trust |
| 242095 | European Community's Seventh Framework Programme | Janse CJ | - | - | - | Longley et al (2015) | This work has been funded by the Wellcome Trust |
| 242095 | European Community's Seventh Framework Programme | - | - | € 12,000,000 | 0.87 € 10,440,000.00 | Forbes et al (2012) | This work was funded by the Wellcome Trust |
| - | European Malaria Vaccine Development Programme | - | - | - | - | Draper et al (2010) | This work was funded by the Wellcome Trust |
| LSHP-CT-2007-037506 | European Malaria Vaccine Development Programme | - | - | - | - | Elias et al (2013) | This work was supported by the Wellcome Trust |
| LSHP-CT-2007-037506 | European Malaria Vaccine Development Programme | de Cassan SC | - | - | - | Payne (2017) | This work was supported by the Wellcome Trust |
| LSHP-CT-2007-037506 | European Malaria Vaccine Development Programme | de Cassan SC | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supported by the Wellcome Trust |
| - | European Malaria Vaccine Development Programme | - | - | - | - | Capone et al (2010) | This work was supported by the Wellcome Trust |
| - | European Malaria Vaccine Initiative | - | - | - | - | Reyes-Sandoval (2010) | Work in the Oxford malaria vaccine development programme |
| - | European Research Council | Walker A | - | - | - | Walker et al (2015) | Andrew S. Walker, José Loureiro |
| - | European Research Council | Lourenço J | - | - | - | Walker et al (2015) | Andrew S. Walker, José Loureiro |
| - | European Research Council | Gupta S | - | - | - | Walker et al (2015) | Andrew S. Walker, José Loureiro |
| 305282 | European Union | MultiMalVax | 01-Oct-12 | € 6,000,000 | 0.87 € 5,220,000.00 | Payne et al (2017) | This work was supported by the Wellcome Trust |
| 316655 | European Union | Halbroth BR | - | - | - | Longley et al (2017) | Funding for manufacture and development |
| 602705 | European Union | Capuccini F | - | - | - | Capuccini et al (2017) | This work was supported by the Wellcome Trust |
| 602705 | European Union | Pollock E | - | - | - | Capuccini et al (2017) | This work was supported by the Wellcome Trust |
| Framework VI;HEPACIVAC | European Union | - | - | - | - | Barnes et al (2012) | European Union (Framework VI) |
| 602705 | European Union's Seventh Framework Programme | Capuccini F | 01-Apr-14 | € 6,000,000 | 0.87 € 5,220,000.00 | Capuccini et al (2016) | This work was supported by the Wellcome Trust |
| 602705 | European Union's Seventh Framework Programme | Pollock E | - | - | - | Capuccini et al (2016) | This work was supported by the Wellcome Trust |
| - | European Vaccine Initiative | - | - | - | - | Cottingham et al (2012) | This work was supported by the Wellcome Trust |
| - | European Vaccine Initiative | - | - | - | - | de Barra et al (2014) | The study was funded by the Wellcome Trust |
| - | European Vaccine Initiative | Chauhan VS | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supported by the Wellcome Trust |
| - | European Vaccine Initiative | Chitnis CE | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supported by the Wellcome Trust |
| - | European Vaccine Initiative | Viebig NK | - | - | - | Kimani et al (2014) | This work was supported by the Wellcome Trust |
| 242095 | EVIMalaria | - | - | - | - | Biswas et al (2014) | This work was supported by the Wellcome Trust |

| | | | | | | | | |
|------------------------|---|---------------------------------------|-----------------|----------|---|-----------------------------|----------------------------------|-------------------------------|
| 242095 | EVIMalaR | - | - | - | | Elias et al (2013) | This work was supported by th | |
| 242095 | EVIMalaR | - | - | - | | Hodgson et al (2014) | This work was supported by th | |
| 242095 | EVIMalaR | Salman M | - | - | | Salman et al (2017) | The work was funded by a We | |
| 242095 | EVIMalaR | - | - | - | | Sheehy et al (2012) | This work was supported by | |
| - | EVIMaIR | Salman AM | - | - | | Longley et al (2015) | This work has been funded by | |
| - | Foundation to NIH | Hill A.V.S | - | - | | Halbroth (2018) | BRH received funding from th | |
| - | Frederick National Laboratory for Cancer | - | - | - | | Tapia et al (2016) | This study was funded by a W | |
| - | Gates Foundation | - | - | - | | Reyes-Sandoval (2010) | Work in the Oxford malaria ve | |
| - | Gates Foundation (through the foundati | - | - | - | | Cottingham et al (2012) | This work was supported by th | |
| - | German Center for Infection Research | - | - | - | | Folegatti P.M.(2020) | UK Department of Health and | |
| - | Graduate Women in Science | Coughlan L | - | - | | Bliss (2020) | This research project was sup | |
| - | Grand Challenges in Global Health | - | - | - | | Reyes-Sandoval et al (2010) | We thank the Jenner Institu | |
| 24659460 | Grant-in-Aid for Challenging Exploratory | Yoshida S | - | - | | Yoshida Klyori (2018) | This work was supported, in p | |
| 26860278 | Grant-in-Aid for Young Scientists | - | - | - | | Yoshida Klyori (2018) | This work was supported, in p | |
| 21390126 | Grants-in-Aid for Scientific Research | - | - | - | | Yoshida Klyori (2018) | This work was supported, in p | |
| 25305007 | Grants-in-Aid for Scientific Research | - | - | - | | Yoshida Klyori (2018) | This work was supported, in p | |
| - | GSK | - | - | - | | Venkatraman N (2019) | This work was supported | |
| - | HAV Vaccines Ltd | - | - | - | | Folegatti P.M. (2019) | This research was funded by t | |
| - | HEPACIVAC | - | - | - | | Swadling et al (2014) | Funding:Supported by the Mer | |
| LSH-2005-1.2.4-2 proje | Hepacivac | - | - | - | | Colloca et al (2012) | This work was supported in p | |
| - | Imperial College NIHR Wellcome Trust C | - | - | - | | Rampling et al (2016) | This work was supported by th | |
| 971510 | Innovate UK | <u>The Jenner Institute, Universi</u> | Apr 17 - May 18 | £483,455 | £ | 483,455.00 | Sebastian S (2020) | This research was funded by I |
| FPI-SGIT-201 | Instituto Nacional de Investigación y Tec | Utrilla-Trigo S | - | - | | Utrilla-Trigo S (2020) | This work was supported by g | |
| - | Irish Aid | - | - | - | | Afolabi et al (2016) | Trials Partnership (EDCTP) anc | |
| - | Irish Aid | - | - | - | | Mensah (2017) | This work was supported by a | |
| - | Irish Aid | - | - | - | | Mensah et al (2016) | This study was supported by a | |
| - | Irish Aid | - | - | - | | Tiono (2018) | This work was supported by a | |
| - | James Martin School for 21st Century, O | - | - | - | | Barnes et al (2012) | European Union (Framework ' | |
| - | Jenner Institue | Gilbert SC | - | - | | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supj | |
| - | Jenner Institue | Hill AVS | - | - | | Dicks et al (2012) | This work has been funded by | |
| - | Jenner Institue | Hill AVS | - | - | | Sheehy et al (2012) | This work was supported by | |
| - | Jenner Institue | Gilbert SC | - | - | | Sheehy et al (2012) | This work was supported by | |
| - | Jenner Institute | Reyes-Sandoval A | - | - | | Atcheson (2018) | The work was funded by a We | |
| - | Jenner Institute | Hill A.V.S | - | - | | Atcheson (2018) | The work was funded by a We | |
| - | Jenner Institute | Hill AVS | - | - | | Bauza et al (2014) | The work was funded by a We | |
| - | Jenner Institute | Reyes-Sandoval A | - | - | | Bauza et al (2014) | The work was funded by a We | |
| - | Jenner Institute | McShane H | - | - | | Betts et al (2012) | Funding was provided by NEW | |
| - | Jenner Institute | Hill AVS | - | - | | Betts et al (2012) | Funding was provided by NEW | |
| - | Jenner Institute | Reyes-Sandoval A | - | - | | Betts et al (2012) | Funding was provided by NEW | |
| - | Jenner Institute | Hill AVS | - | - | | Biswas et al (2014) | This work was supported by th | |
| - | Jenner Institute | Draper SJ | - | - | | Biswas et al (2014) | This work was supported by th | |
| - | Jenner Institute | Hill AVS | - | - | | Carey et al (2013) | This work wassupported by Er | |
| - | Jenner Institute | Gilbert SC | - | - | | Carey et al (2013) | This work wassupported by Er | |
| - | Jenner Institute | Hill AVS | - | - | | de Barra et al (2014) | The study was funded by a gra | |
| - | Jenner Institute | Gilbert SC | - | - | | de Barra et al (2014) | The study was funded by a gra | |
| - | Jenner Institute | Hill AVS | - | - | | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supj | |
| - | Jenner Institute | Draper SJ | - | - | | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supj | |
| - | Jenner Institute | Gilbert SC | - | - | | Dicks et al (2012) | This work has been funded by | |
| - | Jenner Institute | Hill AVS | - | - | | Dicks et al (2015) | This work has been funded by | |
| - | Jenner Institute | Gilbert SC | - | - | | Dicks et al (2015) | This work has been funded by | |
| - | Jenner Institute | Gilbert SC | - | - | | Draper et al (2010) | This work was funded by the \ | |
| - | Jenner Institute | Hill A.V.S. | - | - | | Draper et al (2010) | This work was funded by the \ | |
| - | Jenner Institute | Hill AVS | - | - | | Dulal et al (2016) | This study was conducted with | |
| - | Jenner Institute | Charleston B | - | - | | Dulal et al (2016) | This study was conducted with | |

| | | | | | | |
|-----------|---------------------------------------|---------------------|---|---|-------------------------|-------------------------------|
| - | Jenner Institute | Hill AVS | - | - | Elias et al (2013) | This work was supported by t |
| - | Jenner Institute | Draper SJ | - | - | Elias et al (2013) | This work was supported by t |
| - | Jenner Institute | Hill AVS | - | - | Ewer et al (2013) | The study was funded by gran |
| - | Jenner Institute | Draper SJ | - | - | Ewer et al (2013) | The study was funded by gran |
| - | Jenner Institute | Gilbert SC | - | - | Ewer et al (2013) | The study was funded by gran |
| - | Jenner Institute | Reyes-Sandoval A | - | - | Ewer et al (2013) | The study was funded by gran |
| - | Jenner Institute | Hill AVS | - | - | Forbes et al (2012) | This work was funded by the \ |
| - | Jenner Institute | Draper SJ | - | - | Forbes et al (2012) | This work was funded by the \ |
| - | Jenner Institute | Draper SJ | - | - | Goodman et al (2011) | This work was supported prim |
| - | Jenner Institute | Hill A.V.S | - | - | Goodman et al (2011) | This work was supported prim |
| - | Jenner Institute | Barnes E | - | - | Kelly et al (2016) | Supported by a Medical Resea |
| - | Jenner Institute | Gilbert SC | - | - | Lambe et al (2013) | AvL was funded by a fellowsh |
| - | Jenner Institute | Hill AVS | - | - | Longley et al (2015) | This work has been funded by |
| - | Jenner Institute | Hill AVS | - | - | Longley et al (2017) | Funding for manufacture and |
| - | Jenner Institute | Hill A.V.S | - | - | Payne (2017) | This work was supported by a |
| - | Jenner Institute | Draper SJ | - | - | Payne (2017) | This work was supported by a |
| - | Jenner Institute | Hill AVS | - | - | Payne et al (2017) | This work was supported by ft |
| - | Jenner Institute | Draper SJ | - | - | Payne et al (2017) | This work was supported by ft |
| - | Jenner Institute | Biswas S | - | - | Payne et al (2017) | This work was supported by ft |
| - | Jenner Institute | Reyes-Sandoval A | - | - | Salman et al (2017) | The work was funded by a We |
| - | Jenner Institute | Hill AVS | - | - | Salman et al (2017) | The work was funded by a We |
| - | Jenner Institute | Gilbert SC | - | - | Sheehy et al (2011) | This work was supported by t |
| - | Jenner Institute | Hill AVS | - | - | Sheehy et al (2011) | This work was supported by t |
| - | Jenner Institute | Draper SJ | - | - | Sheehy et al (2011) | This work was supported by t |
| - | Jenner Institute | Gilbert SC | - | - | Sheehy et al (2012 - 2) | This work was supported by t |
| - | Jenner Institute | Draper SJ | - | - | Sheehy et al (2012 - 2) | This work was supported by t |
| - | Jenner Institute | Draper SJ | - | - | Sheehy et al (2012) | This work was supported by t |
| - | Jenner Institute | Gilbert S.C. | - | - | Stedman (2019) | This study was funded by the |
| - | Jenner Institute | Charleston B | - | - | Stedman (2019) | This study was funded by the |
| - | Jenner Institute | A.V.S Hill | - | - | Stedman (2019) | This study was funded by the |
| - | Jenner Institute | Barnes E | - | - | Swadling (2016) | Supported by the Medical Res |
| - | Jenner Institute | Hill AVS | - | - | Walker et al (2015) | Andrew S. Walker, José Loure |
| - | Jenner Institute | Hill A.V.S | - | - | Wang (2018) | This work has been supported |
| - | Jenner Institute | Draper AD | - | - | Wang (2018) | This work has been supported |
| - | Jenner Institute | Douglas SJ | - | - | Wang (2018) | This work has been supported |
| - | Jenner Institute | Hill AVS | - | - | Warimwe et al (2013) | This work was supported by a |
| - | Jenner Institute | Gilbert SC | - | - | Warimwe et al (2013) | This work was supported by a |
| - | Jenner Institute | Hill AVS | - | - | Warimwe et al (2016) | This work was conducted witt |
| - | Jenner Institute | Gilbert SC | - | - | Warimwe et al (2016) | This work was conducted witt |
| - | Jenner Institute | Charleston B | - | - | Warimwe et al (2016) | This work was conducted witt |
| - | Jenner Institute | Hill AVS | - | - | Sheehy et al (2012 - 2) | This work was supported by t |
| - | Jenner Institute | Gilbert S.C. | - | - | Alharbi (2019) | This study is funded by KAIRM |
| - | Jenner Institute | Douglas AD | - | - | Fedosyuk S (2019) | This work was supported by N |
| - | Jenner Institute | Rollier C | - | - | Rollier C (2020) | This work was funded by a gra |
| - | Jenner Institute | Hill A.V.S. | - | - | Rollier C (2020) | This work was funded by a gra |
| - | Jenner Institute | Gilbert S.C. | - | - | Rollier C (2020) | This work was funded by a gra |
| - | Jenner Institute | Gilbert S.C. | - | - | van Doremalen N (2019) | This work was supported by t |
| - | Jenner Vaccine Foundation | - | - | - | Reyes-Sandoval (2010) | Work in the Oxford malaria va |
| RC16/093 | KAIMRC | Naif Khalaf Alharbi | - | - | Alharbi (2019) | This study is funded by KAIRM |
| HI15C2971 | Korean Ministry of Health and Welfare | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| - | Lister Institute | Draper SJ | - | - | Biswas et al (2014) | This work was supported by t |
| - | Lister Institute | Draper SJ | - | - | Elias et al (2013) | This work was supported by t |
| - | Lister Institute | Draper SJ | - | - | Payne (2017) | This work was supported by a |
| - | Lister Institute | Draper SJ | - | - | Payne et al (2017) | This work was supported by ft |
| - | Lister Institute | Draper SJ | - | - | Carey et al (2013) | This work wassupported by Er |

| | | | | | | | |
|---------------------|--|---------------------------------|-----------------|------------|----------------|-----------------------------|---------------------------------|
| - | Lister Institute | Douglas SJ | - | - | - | Wang (2018) | This work has been supported |
| - | Malaria Vaccine Initiative | - | - | - | - | de Barra et al (2014) | The study was funded by a gra |
| - | Malaria Vectored Vaccines Consortium (| - | - | - | - | Ogwang et al (2015) | This work was funded by the f |
| MEST-CT-2005-020492 | MalParTraining | Biswas S | - | - | - | Draper et al (2011) | SB was funded by MalParTrai |
| G0600424 | Medical Research Council | <u>Anna Louise Goodman</u> | Sep 06 - Oct 09 | £159,968 | £ 159,968.00 | Goodman et al (2011) | This work was supported prim |
| - | Meningitis UK | Rollier CS | - | - | - | Reyes-Sandoval et al (2010) | We thank the Jenner Institu |
| - | Merck KGaA | - | - | - | - | Fedosyuk S (2019) | This work was supported by N |
| - | Merton College, Oxford | Draper SJ | - | - | - | Draper et al (2010) | This work was funded by the \ |
| - | Merton College, Oxford | Draper SJ | - | - | - | Draper et al (2011) | SB was funded by MalParTrai |
| - | MEWA, Saudi Arabia | - | - | - | - | Alharbi (2019) | This study is funded by KAIMR |
| - | MRC | - | - | - | - | Bowyer (2018) | The clinical trial was supporte |
| - | MRC | - | - | - | - | Coughlan L (2018) | Medical Research Council UK, |
| - | MRC | Juthathip Mongkolsapaya | - | - | - | Lopez-Camacho (2018) | This report is independent res |
| - | MRC | - | - | - | - | Mensah (2017) | This work was supported by a |
| - | MRC | Warimwe GM | - | - | - | Munster (2017) | This work is published withthe |
| - | MRC | - | - | - | - | Venkatraman N (2019) | This work was supported |
| MC_UU_12014 | MRC | Patel AH, Kohl A | - | - | - | Lopez-Camacho (2018) | This report is independent res |
| MR/P017339/1 | MRC | <u>Alexander Donald Douglas</u> | Apr 17 - Mar 22 | £2,228,194 | £ 2,228,194.00 | Fedosyuk S (2019) | This work was supported by N |
| MR/P017339/1 | MRC | <u>Alexander Donald Douglas</u> | Apr 17 - Mar 22 | £2,228,194 | £ 2,228,194.00 | Wang (2018) | This work has been supported |
| MR/N019008/1 | MRC | Reyes-Sandoval A | Aug 16 - Feb 22 | £1,792,688 | £ 1,792,688.00 | Atcheson (2018) | The work was funded by a We |
| MR/N019008/1 | MRC | Reyes-Sandoval A | Aug 16 - Feb 22 | £1,792,688 | £ 1,792,688.00 | Salman et al (2017) | The work was funded by a We |
| G0701669 | MRC | <u>Tomas Hanke</u> | Oct 08 - Oct 12 | £1,300,519 | £ 1,300,519.00 | Borthwick et al (2014) | The work was supported by |
| MR/L009528/1 | MRC | <u>Thomas Alexander Bowden</u> | Jan 14 - Dec 18 | £1,144,287 | £ 1,144,287.00 | van Doremalen N (2019) | This work was supported by th |
| G1000527 | MRC | Draper SJ | Aug 10 - Jul 15 | £1,104,645 | £ 1,104,645.00 | Biswas et al (2014) | This work was supported by th |
| G1000527 | MRC | Draper SJ | Aug 10 - Jul 15 | £1,104,645 | £ 1,104,645.00 | Carey et al (2013) | This work wassupported by Er |
| G1000527 | MRC | Draper SJ | Aug 10 - Jul 15 | £1,104,645 | £ 1,104,645.00 | Elias et al (2013) | This work was supported by th |
| G1000527 | MRC | Draper SJ | Aug 10 - Jul 15 | £1,104,645 | £ 1,104,645.00 | Sheehy et al (2012 - 2) | This work was supported by th |
| G1100086 | MRC | <u>Simon Draper</u> | Jul 11 - Jun 14 | £895,438 | £ 895,438.00 | Payne (2017) | This work was supported by a |
| G0700735 | MRC | <u>Adrian Hill</u> | Jan 08 - Dec 10 | £748,840 | £ 748,840.00 | Biswas et al (2014) | This work was supported by th |
| G0700735 | MRC | <u>Adrian Hill</u> | Jan 08 - Dec 10 | £748,840 | £ 748,840.00 | Elias et al (2013) | This work was supported by th |
| MR/N006372/1 | MRC | <u>Sarah Catherine Gilbert</u> | Mar 16 - May 18 | £679,559 | £ 679,559.00 | Asthagiri Arunkumar (2019) | The study was fundedby an M |
| MC_PC_13073 | MRC | <u>Chas Bountra</u> | Mar 14 - Sep 15 | £650,000 | £ 650,000.00 | Wang (2018) | This work has been supported |
| G0502018 | MRC | <u>Adrian Hill</u> | Oct 06 - Jan 09 | £647,586 | £ 647,586.00 | O'Hara et al (2012) | Financial support. This work w |
| | | <u>Andrew Michael</u> | | | | | This work was supported, in p |
| MR/N00227X/1 | MRC | <u>Blagborough</u> | Jan 16 - Apr 19 | £549,297 | £ 549,297.00 | Yoshida Klyori (2018) | |
| MC_PC_15040 | MRC | <u>Stephen Ward</u> | Mar 16 - Feb 18 | £500,000 | £ 500,000.00 | Sebastian S (2020) | This research was funded by I |
| G0701694 | MRC | <u>Eleanor Barnes</u> | Aug 09 - Jul 12 | £250,000 | £ 250,000.00 | Kelly et al (2016) | Supported by a Medical Resea |
| G0701694 | MRC | <u>Eleanor Barnes</u> | Aug 09 - Jul 12 | £250,000 | £ 250,000.00 | Swadling (2016) | Supported by the Medical Res |
| MR/N017552/1 | MRC | Kohl A | Jan 16 - Jan 19 | £221,947 | £ 221,947.00 | Lopez-Camacho (2018) | This report is independent res |
| G0600424 | MRC | SJD | - | - | £ 159,968.00 | Goodman et al (2011) | This work was supported prim |
| G0600424 | MRC | Goodman A | Sep 06 - Oct 09 | £159,968 | £ 159,968.00 | Ewer et al (2013) | The study was funded by gran |
| - | MRC | - | - | - | - | Afolabi et al (2016) | Trials Partnership (EDCTP) anc |
| - | MRC | - | - | - | - | Antrobus et al (2014) | The study was funded by gran |
| - | MRC | - | - | - | - | Barnes et al (2012) | European Union (Framework ' |
| - | MRC | Jones EY | - | - | - | Bauza et al (2014) | The work was funded by a We |
| - | MRC | Malinauskas T | - | - | - | Bauza et al (2014) | The work was funded by a We |
| - | MRC | - | - | - | - | Bowyer G (2020) | The Oxford clinical trial was s |
| - | MRC | Stribbling S | - | - | - | Capuccini et al (2016) | This work was supported by O |
| - | MRC | Stribbling S | - | - | - | Capuccini et al (2017) | This work was supported by O |
| - | MRC | Bartirromo M | - | - | - | Colloca et al (2012) | This work was supported in p |
| - | MRC | - | - | - | - | Ewer et al (2013) | The study was funded by gran |
| - | MRC | Draper SJ | - | - | - | Forbes et al (2012) | This work was funded by the \ |

| | | | | | | | |
|-------------------|---|-----------------------------|-----------------|--------------|----------------------|-------------------------|----------------------------------|
| - | MRC | Draper SJ | - | - | - | Goodman et al (2011) | This work was supported prim |
| - | MRC | Goodman AL | - | - | - | Goodman et al (2011) | This work was supported prim |
| - | MRC | Barnes E | - | - | - | Kelly et al (2016) | Supported by a Medical Resea |
| - | MRC | - | - | - | - | Kimani et al (2014) | This work was supported by |
| - | MRC | - | - | - | - | Mensah et al (2016) | This study was supported by a |
| - | MRC | - | - | - | - | Ogwang et al (2013) | This work was performed by t |
| - | MRC | - | - | - | - | Swadling (2016) | Supported by the Medical Res |
| - | MRC | Swadling L | - | - | - | Swadling (2016) | Supported by the Medical Res |
| - | MRC | Barnes E | - | - | - | Swadling (2016) | Supported by the Medical Res |
| - | MRC | - | - | - | - | Swadling et al (2014) | Funding:Supported by the Mei |
| - | MRC | Barnes E | - | - | - | Swadling et al (2014) | Funding:Supported by the Mei |
| - | MRC | Swadling L | - | - | - | Swadling et al (2014) | Funding:Supported by the Mei |
| - | MRC | - | - | - | - | Tapia et al (2016) | This study was funded by a W |
| - | MRC | - | - | - | - | Ewer et al (2016) | Supported by the Wellcome T |
| - | MRC | Swadling L | - | - | - | Kelly et al (2016) | Supported by a Medical Resea |
| G0600311 | MRC | - | - | - | - | Pearson et al (2013) | This work has been supported |
| G0600311 | MRC | - | - | - | - | Pearson et al (2015) | This study was funded by Ente |
| G0600424 | MRC | ALG | Sep 06 - Oct 09 | £159,968 | - | Goodman et al (2011) | This work was supported prim |
| G0700735 | MRC | - | - | - | - | Sheehy et al (2011) | This work was supported by tl |
| G1000157 | MRC | Draper SJ | - | - | - | Sheehy et al (2011) | This work was supported by tl |
| G1000527 | MRC | Draper SJ | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student sup |
| MR/K017632/1) | MRC | Alanine DGW | - | - | - | Payne et al (2017) | This work was supported by ft |
| U117532067 | MRC | Holder AA | - | - | - | Draper et al (2011) | SB was funded by MalParTrai |
| - | MRC and DFID | - | - | - | - | Afolabi et al (2016) | Trials Partnership (EDCTP) anc |
| - | MRC and DFID | - | - | - | - | Afolabi et al (2016) | Trials Partnership (EDCTP) anc |
| - | MRC and DFID | Bejon P | - | - | - | Ogwang et al (2015) | This work was funded by the f |
| - | National Cancer Institute | - | - | - | - | Tapia et al (2016) | This study was funded by a W |
| P51 RR000167 | National Center for Research Resources | - | - | - | - | Rollier C (2020) | This work was funded by a gra |
| RR020141 | National Center for Research Resources | - | - | - | - | Rollier C (2020) | This work was funded by a gra |
| RR15459 | National Center for Research Resources | - | - | - | - | Rollier C (2020) | This work was funded by a gra |
| P51 RR000167 | National Centre for Research Resources | - | - | - | - | Spencer et al (2014) | This work has been funded by |
| RR020141 | National Centre for Research Resources | - | - | - | - | Spencer et al (2014) | This work has been funded by |
| RR15459 | National Centre for Research Resources | - | - | - | - | Spencer et al (2014) | This work has been funded by |
| - | National Health Service Blood and Trans | - | - | - | - | Ewer et al (2016) | Supported by the Wellcome T |
| - | National Insitute of Health and Researc | - | - | - | - | Tiono (2018) | This work was supported by a |
| - | National Institue of Allergy and Infectio | - | - | - | - | Sheehy et al (2012 - 2) | This work was supported by tl |
| - | National Institute for Health and Resear | - | - | - | - | Barnes et al (2012) | European Union (Framework ' |
| - | National Institute for Health Research | - | - | - | - | Bowyer G (2020) | The Oxford clinical trial was s |
| - | National Institute for Health Research | - | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supj |
| - | National Institute for Health Research | - | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| - | National Institute for Health Research | Rollier C | - | - | - | Rollier C (2020) | This work was funded by a gra |
| - | National Institute for Health Research | Hill A.V.S. | - | - | - | Rollier C (2020) | This work was funded by a gra |
| - | National Institute for Health Research | - | - | - | - | van Doremalen N (2020) | This work was supported by tl |
| - | National Institute for Health Research | - | - | - | - | van Doremalen N (2020) | This work was supported by tl |
| - | National Institute of Allergy and Infectio | - | - | - | - | Sheehy et al (2012) | This work was supported by |
| HHSN272201400008C | National Institute of Allergy and Infectio | Icahn School Of Medicine At | 09/01/2014 | \$78,100,000 | 0.72 £ 56,232,000.00 | S Graham (2020) | Developmentof SARS-CoV-2 r |
| - | National Institute of Allergy and Infectio | - | - | - | - | Biswas et al (2014) | This work was supported by tl |
| - | National Institute of Allergy and Infectious Diseases | - | - | - | - | Sheehy et al (2011) | This work was supported by tl |
| - | National Institute of Allergy and Infectio | - | - | - | - | Tapia et al (2016) | This study was funded by a W |
| - | National Institute of Allergy and Infectio | EMMES Corporation | - | - | - | Tapia et al (2016) | This study was funded by a W |
| HHSN261200800001E | National Institute of Allergy and Infectio | Leidos Biomedical Research | - | - | - | Tapia et al (2016) | This study was funded by a W |
| R44AI058375 | National Institute of Allergy and Infectio | - | - | - | - | Longley et al (2017) | Funding for manufacture and |
| - | National Institute of Allergy and Infectious Diseases | - | - | - | - | Draper et al (2011) | SB was funded by MalParTrai |

| | | | | | | | | | | |
|-------------------|---|---------------------------|-----------|-------------|--|------|---|-----------------------------|---------------------------------|-------------------------------|
| | National Institute of Allergy and Infectio | - | - | | | | | Payne et al (2017) | This work was supported by f | |
| | National Institute of Allergy and Infectio | - | - | | | | | van Doremalen N (2019) | This work was supported by tl | |
| | National Institute of Allergy and Infectio | - | - | | | | | van Doremalen N (2020) | This work was supported by tl | |
| | National Institute of Allergy and Infectio | - | - | | | | | van Doremalen N (2020) | This work was supported by tl | |
| HHSN272201400008C | National Institute of Allergy and Infectio | - | - | | | | | van Doremalen N (2020) | This work was supported by tl | |
| | National Institute of Health | - | - | | | | | Biswas et al (2014) | This work was supported by tl | |
| | National Institute of Health | - | - | | | | | Folegatti P.M. (2019) | This research was funded by t | |
| | National Institute of Health | Hill A.V.S | - | | | | | Gola (2018) | A.G. is funded by the Wellcor | |
| | National Institute of Health | - | - | | | | | Reyes-Sandoval (2010) | Work in the Oxford malaria va | |
| | National Institute of Health | - | - | | | | | Rollier C (2020) | This work was funded by a gra | |
| | National Institute of Health | - | - | | | | | Sheehy et al (2012) | This work was supported by | |
| | National Institute of Health | - | - | | | | | Sheehy et al (2012 - 2) | This work was supported by tl | |
| HHSN272201400008C | National Institute of Health | - | - | | | | | Bliss (2020) | This research project was sup | |
| | National Institute of Health | - | - | | | | | Draper et al (2011) | SB was funded by MalParTrai | |
| HILL05GCGHO | National Institute of Health | - | - | | | | | Spencer et al (2014) | This work has been funded by | |
| | National Institute of Health and Researc | - | - | | | | | Bowyer (2018) | The clinical trial was supporte | |
| | National Institute of Health and Researc | - | - | | | | | Coughlan L (2018) | Medical Research Council UK, | |
| | National Institute of Health and Researc | - | - | | | | | Venkatraman N (2019) | This work was supported | |
| | National Institute of Health and Researc | - | - | | | | | Bliss (2018) | This study was funded by the | |
| | National Institutes of Allergy and Infecti- | - | - | | | | | Forbes et al (2012) | This work was funded by the \ | |
| 1ZIAI001179-01 | National Institutes of Health | <u>MUNSTER, VINCENT</u> | 2013 | \$877,861 | | 0.72 | £ | 632,059.92 | van Doremalen N (2020) | This work was supported by tl |
| | National Institutes of Health | - | - | | | | | Forbes et al (2012) | This work was funded by the \ | |
| | National Institutes of Health | - | - | | | | | Sheehy et al (2011) | This work was supported by tl | |
| | National Institutes of Health, National Ir | - | - | | | | | Hodgson et al (2014) | This work was supported by tl | |
| | NDM | Biswas S | - | | | | | Biswas et al (2014) | This work was supported by tl | |
| 26-6. | NEKKEN | Iyori M | 2014 | - | | | | Yoshida Klyori (2018) | This work was supported, in p | |
| 27-5. | NEKKEN | Iyori M | 2015 | - | | | | Yoshida Klyori (2018) | This work was supported, in p | |
| EC FP7 | NEWTBVAC | - | - | | | | | Betts et al (2012) | Funding was provided by NEW | |
| | 1041802 NHMRC | McCarthy JS | - | | | | | Payne (2017) | This work was supported by a | |
| | 10418020 NHMRC | McCarthy JS | - | | | | | Payne et al (2017) | This work was supported by ft | |
| 5T32AI007647-17 | NIAID | PALESE, PETER | 04-May-16 | \$523,884 | | 0.72 | £ | 377,196.48 | Asthagiri Arunkumar (2019) | The study was fundedby an M |
| 1R03AI142046-01 | NIAID | <u>ALBRECHT, RANDY A.</u> | 01-Dec-18 | \$84,750 | | 0.72 | £ | 61,020.00 | McHanon M (2019) | The study was fundedby an M |
| | NIAID | Gola A | - | | | | | Gola (2018) | A.G. is funded by the Wellcor | |
| | NIAID | Uderhardt S | - | | | | | Gola (2018) | A.G. is funded by the Wellcor | |
| | NIAID | Germain RN | - | | | | | Gola (2018) | A.G. is funded by the Wellcor | |
| | NIAID | - | - | | | | | Munster (2017) | This work is published withthe | |
| AI109946 | NIAID | - | - | | | | | McHanon M (2019) | The study was fundedby an M | |
| HHSN272201400008C | NIAID | - | - | | | | | Asthagiri Arunkumar (2019) | The study was fundedby an M | |
| HHSN272201400008C | NIAID | - | - | | | | | McHanon M (2019) | The study was fundedby an M | |
| 1U19AI082630-01 | NIH | <u>CHUNG, RAYMOND T</u> | 07-Jun-09 | \$3,086,377 | | 0.72 | £ | 2,222,191.44 | Barnes et al (2012) | European Union (Framework' |
| 2U19AI082630-06 | NIH | <u>CHUNG, RAYMOND T</u> | 30-May-14 | \$2,351,111 | | 0.72 | £ | 1,692,799.92 | Kelly et al (2016) | Supported by a Medical Resea |
| | NIH | - | - | | | | | Munster (2017) | This work is published withthe | |
| 2U19AI082630-06 | NIH | Klenerman P | - | | | | | Kelly et al (2016) | Supported by a Medical Resea | |
| 2U19AI082630-06 | NIH | Kelly C | - | | | | | Swadling (2016) | Supported by the Medical Res | |
| 2U19AI082630-06 | NIH | Klenerman P | - | | | | | Swadling (2016) | Supported by the Medical Res | |
| HILL05GCGHO | NIH | - | - | | | | | Dicks et al (2015 - 2) | This work has been funded by | |
| | NIH foundation | - | - | | | | | Dicks et al (2012) | This work has been funded by | |
| | NIHR | - | - | | | | | Mensah (2017) | This work was supported by a | |
| | NIHR | - | - | | | | | Payne (2017) | This work was supported by a | |
| | NIHR | Hill AVS | - | | | | | Walker et al (2015) | Andrew S. Walker, José Loure | |
| | NIHR | Hill AVS | - | | | | | Ewer et al (2013) | The study was funded by gran | |
| | NIHR | - | - | | | | | Reyes-Sandoval et al (2010) | We thank the Jenner Institu | |
| | NIHR (Oxford Biomedical Research Cent | - | - | | | | | O'Hara et al (2012) | Financial support. This work w | |

| | | | | | |
|----------------------|--|---|---|-----------------------------|----------------------------------|
| A91301 Adult Vaccine | NIHR (through Oxford Biomedical Resea | - | - | Sheehy et al (2011) | This work was supported by t |
| - | NIHR Oxford Biomedical Research Centr | - | - | Antrobus et al (2014) | The study was funded by gran |
| - | NIHR Oxford Biomedical Research Centr | - | - | Cottingham et al (2012) | This work was supported by t |
| - | NIHR Oxford Biomedical Research Centr | - | - | Elias et al (2013) | This work was supported by t |
| - | NIHR Oxford Biomedical Research Centr Barnes E | - | - | Swadling et al (2014) | Funding:Supported by the Mei |
| - | NIHR Oxford Biomedical Research Centr | - | - | Ewer et al (2013) | The study was funded by gran |
| 084113/Z/07/Z | NIHR Oxford Biomedical Research Centr | - | - | Biswas et al (2014) | This work was supported by t |
| A91301 Adult Vaccine | NIHR Oxford Biomedical Research Centr | - | - | de Barra et al (2014) | The study was funded by a gr |
| A91301 Adult Vaccine | NIHR Oxford Biomedical Research Centr | - | - | Kimani et al (2014) | This work was supported by |
| A91301 Adult Vaccine | NIHR Oxford Biomedical Research Centr | - | - | Ogwang et al (2013) | This work was performed by t |
| A91301 Adult Vaccine | NIHR Oxford Biomedical Research Centr | - | - | Sheehy et al (2012 - 2) | This work was supported by t |
| A91301 Adult Vaccine | NIHR Oxford Biomedical Research Centr | - | - | Sheehy et al (2012) | This work was supported by |
| A91301 Adult Vaccine | NIHR Oxford Biomedical Research Centr | - | - | Hodgson et al (2014) | This work was supported by t |
| A91301,Adult Vaccine | NIHR Oxford Biomedical Research Centr | - | - | Hodgson et al (2015) | This work was supported by t |
| - | NIHR Oxford BRC | - | - | Capuccini et al (2017) | This work was supported by C |
| - | NIHR Oxford BRC | - | - | Ewer et al (2016) | Supported by the Wellcome T |
| - | NIHR Oxford BRC | - | - | Longley et al (2017) | Funding for manufacture and |
| - | NIHR Oxford BRC | - | - | Payne et al (2017) | This work was supported by fi |
| - | NIHR Oxford BRC | - | - | Rampling et al (2016) | This work was supported by t |
| - | NIHR Oxford BRC Kelly C | - | - | Swadling (2016) | Supported by the Medical Res |
| - | NIHR Oxford BRC Klenerman P | - | - | Swadling (2016) | Supported by the Medical Res |
| - | NIHR Oxford BRC Barnes E | - | - | Swadling (2016) | Supported by the Medical Res |
| 91301 Adult Vaccine | NIHR Oxford BRC | - | - | Afolabi et al (2016) | Trials Partnership (EDCTP) anc |
| 58-5348-2-117F | Norman Borlaug Commemorative Resea | - | - | Svitek (2018) | This work was funded by the I |
| - | Nuffield Department of Medicine Reyes-Sandoval A | - | - | Reyes-Sandoval et al (2010) | We thank the Jenner Institu |
| - | Nuffield Department of Medicine Longley RJ | - | - | Longley et al (2015) | This work has been funded by |
| - | Nuffield Department of Medicine Longley RJ | - | - | Longley et al (2017) | Funding for manufacture and |
| - | Oak Foundation | - | - | Stedman (2019) | This study was funded by the |
| 16/107/05 | ODA budget Reyes-Sandoval A, Patel AH | - | - | Lopez-Camacho (2018) | This report is independent res |
| - | Ohyama Health Foundation | - | - | Yoshida Klyori (2018) | This work was supported, in p |
| - | Oxford Biomedical Research Centre | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supj |
| - | Oxford Biomedical Research Centre Rollier CS | - | - | Reyes-Sandoval et al (2010) | We thank the Jenner Institu |
| - | Oxford Martin Institute Spencer AJ | - | - | Longley et al (2017) | Funding for manufacture and |
| - | Oxford Martin Institute Hill AVS | - | - | Salman et al (2017) | The work was funded by a We |
| - | Oxford Martin School Reyes-Sandoval A | - | - | Atcheson (2018) | The work was funded by a We |
| - | Oxford Martin School Hill A.V.S | - | - | Atcheson (2018) | The work was funded by a We |
| - | Oxford Martin School Reyes-Sandoval A | - | - | Bauza et al (2014) | The work was funded by a We |
| - | Oxford Martin School | - | - | Cottingham et al (2012) | This work was supported by t |
| - | Oxford Martin School Barnes E | - | - | Kelly et al (2016) | Supported by a Medical Resea |
| - | Oxford Martin School Lambe T | - | - | Lambe et al (2013) | AVL was funded by a fellowsh |
| - | Oxford Martin School Spencer AJ | - | - | Longley et al (2015) | This work has been funded by |
| - | Oxford Martin School Reyes-Sandoval A | - | - | Salman et al (2017) | The work was funded by a We |
| - | Oxford Martin School Barnes E | - | - | Swadling (2016) | Supported by the Medical Res |
| - | Oxford Martin School Hill AVS | - | - | Bauza et al (2014) | The work was funded by a We |
| - | Oxford Martin School | - | - | Antrobus et al (2014) | The study was funded by gran |
| - | Oxford Martin School Spencer AJ | - | - | Dicks et al (2015) | This work has been funded by |
| - | Oxford Martin School Cottingham MG | - | - | Dicks et al (2015) | This work has been funded by |
| - | Oxford Martin School Cottingham MG | - | - | Dicks et al (2012) | This work has been funded by |
| - | Oxford Martin Schools Barnes E | - | - | Swadling et al (2014) | Funding:Supported by the Mei |

| | | | | | | | |
|-------------------|--|--------------------------------|-----------------|-------------|-----------------|---|--------------------------------------|
| - | Oxford NHRBRC | - | - | - | - | Kelly et al (2016) | Supported by a Medical Resea |
| - | Oxford NHRBRC | Barnes E | - | - | - | Kelly et al (2016) | Supported by a Medical Resea |
| - | Oxford NIHR Biomedical Research Centr | - | - | - | - | Barnes et al (2012) | European Union (Framework 1 |
| - | Oxford NIHR Biomedical Research Centr | Redchenko I | - | - | - | Capuccini et al (2016) | This work was supported by O |
| - | PATH Malaria Vaccine Initiative | - | - | - | - | Forbes et al (2012) | This work was funded by the \ |
| - | PATH Malaria Vaccine Initiative | - | - | - | - | Hodgson et al (2014) | This work was supported by th |
| - | PATH Malaria Vaccine Initiative | - | - | - | - | Rampling T (2018) | This work was funded primari |
| - | PATH Malaria Vaccine Initiative | - | - | - | - | Sheehy et al (2012) | This work was supported by |
| - | PATH Malaria Vaccine Initiative | - | - | - | - | Biswas et al (2014) | This work was supported by th |
| - | PATH Malaria Vaccine Initiative | - | - | - | - | Rampling et al (2016) | This work was supported by th |
| - | PATH Malaria Vaccine Initiative (MVI) | - | - | - | - | Sheehy et al (2011) | This work was supported by th |
| - | PATH MalariaVaccine Initiative | - | - | - | - | Hodgson et al (2015) | This work was supported by th |
| - | PATH MalariaVaccineInitiative | - | - | - | - | Sheehy et al (2012 - 2) | This work was supported by th |
| - | PATH-MVI Malaria Vaccine Initiative | - | - | - | - | Draper et al (2011) | SB was funded by MalParTrail |
| - | Public Health England | - | - | - | - | Ewer et al (2016) | Supported by the Wellcome T |
| - | ReiThera (formerly Okairos) | Nicosia A | - | - | - | Mensah et al (2016) | This study was supported by a |
| - | Rhodes Trust | - | - | - | - | Longley et al (2015) | This work has been funded by |
| - | Rhodes Trust | Longley RJ | - | - | - | Longley et al (2017) | Funding for manufacture and |
| - | Rhodes Trust | Llewellyn D | - | - | - | Payne (2017) | This work was supported by a |
| - | Science Foundation Ireland | - | - | - | - | Carey et al (2013) | This work wassupported by Er |
| NAP156 | Science Foundation Ireland | - | - | - | - | Pearson et al (2015) | This study was funded by Ente |
| NAP170 | Science Foundation Ireland | - | - | - | - | Pearson et al (2015) | This study was funded by Ente |
| - | Southampton NIHR Wellcome Trust Clin | - | - | - | - | Sheehy et al (2012) | This work was supported by |
| - | Southampton NIHR Wellcome Trust Clin | - | - | - | - | Rampling et al (2016) | This work was supported by th |
| AGL2017-82570-R | Spanish Ministry of Science | - | - | - | - | Utrilla-Trigo S (2020) | This work was supported by g |
| - | Spanish Ministry of Science | Lopez-Gil E | - | - | - | Warimwe et al (2013) | This work was supported by a |
| AGL2011-22485 | Spanish Ministry of Science | Brun AV | - | - | - | Warimwe et al (2013) | This work was supported by a |
| - | St Catherine's College, Oxford | Biswas S | - | - | - | Biswas et al (2014) | This work was supported by th |
| - | Swedish International Development Coo | - | - | - | - | Afolabi et al (2016) | Trials Partnership (EDCTP) anc |
| - | Swedish International Development Coo | - | - | - | - | Mensah (2017) | This work was supported by a |
| - | Swedish International Development Coo | - | - | - | - | Mensah et al (2016) | This study was supported by a |
| - | Swedish International Development Coo | - | - | - | - | Tiono (2018) | This work was supported by a |
| - | The Coalition for Epidemic Preparedness | - | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| - | The Oxford Martin School | Rollier CS | - | - | - | Reyes-Sandoval et al (2010) | We thank the Jenner Institu |
| EU FP7 | Transmolec | - | - | - | - | Goodman et al (2011) | This work was supported prim |
| EU FP7 | Transmolec | - | - | - | - | Goodman et al (2011) | This work was supported prim |
| - | TRANSVAC | - | - | - | - | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supj |
| - | UK Department for International Develo | - | - | - | - | Bowyer G (2020) | The Oxford clinical trial was s |
| - | UK Department for International Develo | - | - | - | - | Venkatraman N (2019) | This work was supported |
| Project 16/107/03 | UK Department of Health and Social Car | - | - | - | - | Stedman (2019) | This study was funded by the |
| 16/107/01 | UK Department of Health and Social Car | - | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| EP/R013756/1 | UK Engineering and Physical Sciences Re | - | - | £6,968,179 | £ 6,968,179.00 | Fedosyuk S (2019) | This work was supported by Iv |
| - | UK Medical Research Council | - | - | - | - | Reyes-Sandoval (2010) | Work in the Oxford malaria va |
| - | UK National Institute for Health Researc | - | - | - | - | Folegatti P.M.(2020) | UK Department of Health and |
| MC_PC_19055 | UK Research and Innovation | <u>Sarah Catherine Gilbert</u> | Apr 20 - Sep 21 | £2,174,847 | £ 2,174,847.00 | Folegatti P.M.(2020) | UK Research and Innovation, (|
| GR000550 | UK Royal Society for Tropical Medicine a | Coughlan L | - | - | - | Bliss (2020) | This research project was sup |
| 972216 | UKRI | Reyes-Sandoval A | Oct 16 - Sep 17 | £498,870 | £ 498,870.00 | Lopez-Camacho (2018) | This report is independent res |
| | UKRI | Alexandar Douglas | | £411,388.00 | £ 411,388.00 | https://www.ukri.org/research/c | This COVID-19 Rapid Respons |
| | UKRI | Sandy Douglas | | £400,000.00 | £ 400,000.00 | https://www.ox.ac.uk/news/202 | Working with Professor Sarah Gilbert |
| | UKRI | Graham Ogg | | £246,000.00 | £ 246,000.00 | https://www.ukri.org/rese | This £246k award is to procur |
| BBS/E/I/00007037 | UKRI Biotechnology and BiologicalScienc | <u>Michael Johnson</u> | Apr 17 - Mar 20 | £17,455,044 | £ 17,455,044.00 | S Graham (2020) | UKRI Biotechnology and Biolc |
| BBS/E/I/00007039 | UKRI Biotechnology and BiologicalScienc | <u>Simon Thomas Carpenter</u> | Apr 17 - Mar 20 | £6,662,753 | £ 6,662,753.00 | S Graham (2020) | UKRI Biotechnology and Biolc |
| BBS/E/I/00007031 | UKRI Biotechnology and BiologicalScienc | <u>Philippa Beard</u> | Apr 17 - Mar 20 | £2,965,523 | £ 2,965,523.00 | S Graham (2020) | UKRI Biotechnology and Biolc |
| BBS/E/I/00007034 | UKRI Biotechnology and BiologicalScienc | <u>Simon Thomas Carpenter</u> | Apr 17 - Mar 20 | £2,728,186 | £ 2,728,186.00 | S Graham (2020) | UKRI Biotechnology and Biolc |

| | | | | | | | |
|-----------------|--|--------------------------|-----------------|---------------|----------------|-----------------------------|---------------------------------|
| EP/R013756/1 | UKRI Engineering and Physical Sciences | Tarit K Mukhopadhyay | Apr 18 - Sep 21 | £6,968,179 | £ 6,968,179.00 | S Graham (2020) | This study was supported by L |
| EP/S025243/1 | UKRI Engineering and Physical Sciences | James Henderson Naismith | Nov 18 - May 20 | £1,649,512 | £ 1,649,512.00 | S Graham (2020) | andEPSRC Grant No. EP/S025: |
| - | University of Oxford | - | - | - | - | Warimwe et al (2016) | This work was conducted with |
| MRF/TT2015/2150 | University of Oxford | Coughlan L | - | - | - | Bliss (2020) | This research project was sup |
| - | USAID | - | - | - | - | Payne et al (2017) | This work was supported by fi |
| - | Vaccine Research Center | - | - | - | - | Tapia et al (2016) | This study was funded by a W |
| - | Vaccitech Ltd | - | - | - | - | Tuthill M. (2020) | European Union Seventh Fram |
| - | Wellcome Trust | - | - | - | - | Ewer et al (2013) | The study was funded by gran |
| 76438 | Wellcome Trust | - | - | - | - | Reyes-Sandoval et al (2010) | We thank the Jenner Institu |
| 206194 | Wellcome Trust | - | - | - | - | Payne et al (2017) | This work was supported by fi |
| - | Wellcome Trust | - | - | - | - | Bowyer G (2020) | The Oxford clinical trial was s |
| - | Wellcome Trust | AVSH | - | - | - | Capone et al (2010) | This work was supported by tl |
| - | Wellcome Trust | - | - | - | - | Capone et al (2010) | This work was supported by tl |
| - | Wellcome Trust | Hill AVS | - | - | - | Capuccini et al (2017) | This work was supported by O |
| - | Wellcome Trust | - | - | - | - | Reyes-Sandoval (2010) | Work in the Oxford malaria va |
| - | Wellcome Trust | Reyes-Sandoval A | - | - | - | Reyes-Sandoval et al (2010) | We thank the Jenner Institu |
| - | Wellcome Trust | - | - | - | - | Rollier C (2020) | This work was funded by a gra |
| - | Wellcome Trust | Hill A.V.S. | - | - | - | Rollier C (2020) | This work was funded by a gra |
| - | Wellcome Trust | - | - | - | - | Venkatraman N (2019) | This work was supported |
| 084113/Z/07/Z | Wellcome Trust | - | - | - | - | Afolabi et al (2016) | Trials Partnership (EDCTP) and |
| 084113/Z/07/Z | Wellcome Trust | - | - | - | - | Longley et al (2017) | Funding for manufacture and |
| 084113/Z/07/Z | Wellcome Trust | - | - | - | - | Payne et al (2017) | This work was supported by fi |
| 095540/Z/11/Z | Wellcome Trust | Hill AVS | - | - | - | Longley et al (2017) | Funding for manufacture and |
| 095540/Z/11/Z | Wellcome Trust | Hill AVS | - | - | - | Salman et al (2017) | The work was funded by a We |
| 097395/Z/11/Z | Wellcome Trust | Reyes-Sandoval A | - | - | - | Alves et al (2017) | The work was funded by a We |
| 097395/Z/11/Z | Wellcome Trust | Reyes-Sandoval A | - | - | - | Salman et al (2017) | The work was funded by a We |
| 097940/Z/11/Z | Wellcome Trust | Hodgson SH | - | - | - | Longley et al (2017) | Funding for manufacture and |
| 106917/Z/15/Z | Wellcome Trust | Draper SJ | - | - | - | Payne et al (2017) | This work was supported by fi |
| 204826/Z/16/Z | Wellcome Trust | Prof Matthew Freeman | 07/09/2016 | £3,000,000.00 | £ 3,000,000.00 | Fedosyuk S (2019) | This work was supported by N |
| 106917/Z/15/Z | Wellcome Trust | Prof Simon Draper | 01/04/2015 | £1,901,424.00 | £ 1,901,424.00 | Wang (2018) | This work has been supported |
| 095540/Z/11/Z | Wellcome Trust | Hill A.V.S | 10/05/2011 | £1,372,456.00 | £ 1,372,456.00 | Atcheson (2018) | The work was funded by a We |
| 95540/Z/11/Z | Wellcome Trust | Prof Adrian Hill | 10/05/2011 | £1,372,456.00 | £ 1,372,456.00 | Dicks et al (2015 - 2) | This work has been funded by |
| 97395/Z/11/Z | Wellcome Trust | Reyes-Sandoval A | 12/12/2011 | £1,081,461.00 | £ 1,081,461.00 | Bauza et al (2014) | The work was funded by a We |
| 201477/Z/16/Z | Wellcome Trust | Dr Alexander Douglas | 18/05/2016 | £414,492.00 | £ 414,492.00 | Wang (2018) | This work has been supported |
| 201477/Z/16/Z | Wellcome Trust | Douglas AD | 18/05/2016 | £414,492.00 | £ 414,492.00 | Fedosyuk S (2019) | This work was supported by N |
| 098635/B/12/Z | Wellcome Trust | Warimwe GM | 21/06/2012 | £253,778.00 | £ 253,778.00 | Dulal et al (2016) | This study was conducted with |
| 098635/B/12/Z | Wellcome Trust | Warimwe GM | 21/06/2012 | £253,778.00 | £ 253,778.00 | Warimwe et al (2013) | This work was supported by a |
| 094449/Z/10/Z | Wellcome Trust | Duncan CJ | 31/08/2010 | £218,216.00 | £ 218,216.00 | Sheehy et al (2012) | This work was supported by |
| 089455/Z/09/Z | Wellcome Trust | Douglas AD | 29/05/2009 | £217,651 | £ 217,651.00 | Payne et al (2017) | This work was supported by fi |
| 97395/Z/11/A | Wellcome Trust | Reyes-Sandoval A | 01/08/2013 | £203,200.00 | £ 203,200.00 | | |
| 097940/Z/11/Z | Wellcome Trust | Hodgson SH | 29/03/2012 | £195,304.00 | £ 195,304.00 | Kimani et al (2014) | This work was supported by |
| 76438 | Wellcome Trust | Prof Adrian Hill | 16/09/2008 | £84,023.00 | £ 84,023.00 | Reyes-Sandoval et al (2008) | The work was supported by a |
| 098635/Z/12/Z | Wellcome Trust | Warimwe GM | 21/06/2012 | £74,551.00 | £ 74,551.00 | Dulal et al (2016) | This study was conducted with |
| - | Wellcome Trust | - | - | - | - | Barnes et al (2012) | European Union (Framework ') |

| | | | | |
|---------------|----------------|------------------|---|---|
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Hill AVS | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Hill AVS | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Hill AVS | - | - |
| - | Wellcome Trust | Hill A.V.S | - | - |
| - | Wellcome Trust | Hill A.V.S. | - | - |
| - | Wellcome Trust | Gilbert SC | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Hill AVS | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Hill AVS | - | - |
| - | Wellcome Trust | Hill A.V.S | - | - |
| - | Wellcome Trust | Hill A.V.S | - | - |
| - | Wellcome Trust | Hill A.V.S. | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Gavin Screaton | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Hill AVS | - | - |
| - | Wellcome Trust | Hill A.V.S | - | - |
| - | Wellcome Trust | Hill AVS | - | - |
| - | Wellcome Trust | - | - | - |
| - | Wellcome Trust | Kelly C | - | - |
| - | Wellcome Trust | Klenerman P | - | - |
| 084113/Z/07/Z | Wellcome Trust | - | - | - |
| 084113/Z/07/Z | Wellcome Trust | - | - | - |
| 084113/Z/07/Z | Wellcome Trust | - | - | - |
| 084113/Z/07/Z | Wellcome Trust | Hill AVS | - | - |
| 084113/Z/07/Z | Wellcome Trust | - | - | - |
| 084113/Z/07/Z | Wellcome Trust | - | - | - |
| 084113/Z/07/Z | Wellcome Trust | - | - | - |
| 084113/Z/07/Z | Wellcome Trust | - | - | - |
| 084113/Z/07/Z | Wellcome Trust | Prof Adrian Hill | - | - |
| 091663MA | Wellcome Trust | - | - | - |
| 095540/Z/11/Z | Wellcome Trust | - | - | - |
| 095540/Z/11/Z | Wellcome Trust | - | - | - |
| 095540/Z/11/Z | Wellcome Trust | - | - | - |
| 097940/Z/11/Z | Wellcome Trust | Hodgson SH | - | - |
| 097940/Z/11/Z | Wellcome Trust | Hodgson SH | - | - |
| 097940/Z/11/Z | Wellcome Trust | Hodgson SH | - | - |
| 099897/Z/12/A | Wellcome Trust | - | - | - |
| 45488/Z/05 | Wellcome Trust | Hill AVS | - | - |
| 45488/Z/05 | Wellcome Trust | Hill AVS | - | - |
| 45488/Z/05 | Wellcome Trust | Hill AVS | - | - |
| 45488/Z/05 | Wellcome Trust | Hill AVS | - | - |
| 45488/Z/05 | Wellcome Trust | Hill AVS | - | - |
| 45488/Z/05 | Wellcome Trust | Hill AVS | - | - |
| RTEIO | Wellcome Trust | Duncan CJ | - | - |
| WT076943MA | Wellcome Trust | McShane H | - | - |
| WT098051 | Wellcome Trust | - | - | - |
| WT098635 | Wellcome Trust | Warimwe GM | - | - |

Bliss (2018) This study was funded by the
Boyd et al (2013) The Biotechnology and Biolog
Capuccini et al (2016) This work was supported by O
Colloca et al (2012) This work was supported in p
Cottingham et al (2012) This work was supported by th
de Cassan et al (2011) S.C.d.C. is a Ph.D. student supj
Dicks et al (2012) This work has been funded by
Dicks et al (2015 - 2) This work has been funded by
Draper et al (2010) This work was funded by the \
Draper et al (2011) SB was funded by MalParTrai
Draper et al (2011) SB was funded by MalParTrai
Ewer et al (2013) The study was funded by gran
Ewer et al (2013) The study was funded by gran
Forbes et al (2012) This work was funded by the \
Forbes et al (2012) This work was funded by the \
Gola (2018) A.G. is funded by the Wellcorr
Gola (2018) A.G. is funded by the Wellcorr
Goodman et al (2011) This work was supported prim
Halbroth (2018) BRH received funding from th
Kelly et al (2016) Supported by a Medical Resea
Lopez-Camacho (2018) This report is independent res
Tapia et al (2016) This study was funded by a W
Tapia et al (2016) This study was funded by a W
Walker et al (2015) Andrew S. Walker, José Loure
Halbroth (2018) BRH received funding from th
Colloca et al (2012) This work was supported in p
Ewer et al (2016) Supported by the Wellcome T
Swadling (2016) Supported by the Medical Res
Swadling (2016) Supported by the Medical Res
de Barra et al (2014) The study was funded by a gr
Elias et al (2013) This work was supported by tl
Hodgson et al (2014) This work was supported by tl
Hodgson et al (2015) This work was supported by tl
Kimani et al (2014) This work was supported by
Sheehy et al (2011) This work was supported by tl
Sheehy et al (2012 - 2) This work was supported by tl
Sheehy et al (2012) This work was supported by
Colston et al (2016) This work was supported by W
Dicks et al (2015) This work has been funded by
Longley et al (2015) This work has been funded by
Spencer et al (2014) This work has been funded by
de Barra et al (2014) The study was funded by a gr
Hodgson et al (2015) This work was supported by tl
Biswas et al (2014) This work was supported by tl
Colston et al (2016) This work was supported by W
de Barra et al (2014) The study was funded by a gr
Hodgson et al (2015) This work was supported by tl
Sheehy et al (2011) This work was supported by tl
Sheehy et al (2012 - 2) This work was supported by tl
Sheehy et al (2012) This work was supported by tl
Sheehy et al (2012 - 2) This work was supported by tl
Betts et al (2012) Funding was provided by NEV
Bauza et al (2014) The work was funded by a We
Warimwe et al (2016) This work was conducted with

| | | | | | | | |
|---------------|--|-------------------|------------|----------------|-----------------|------------------------|----------------------------------|
| 97395 | Wellcome Trust | Reyes-Sandoval A | - | - | - | Betts et al (2012) | Funding was provided by NEW |
| - | Wellcome Trust | Hill AVS | - | - | - | Dicks et al (2012) | This work has been funded by |
| - | Wellcome Trust | - | - | - | - | O'Hara et al (2012) | Financial support. This work w |
| 084113/Z/07/Z | Wellcome Trust | - | - | - | - | Ogwang et al (2013) | This work was performed by t |
| WT 098051 | Wellcome Trust | Otto TD | - | - | - | Payne (2017) | This work was supported by a |
| 203077/Z/16/Z | Wellcome Trust | Prof Philip Bejon | 30/06/2016 | £26,595,243.00 | £ 26,595,243.00 | Stedman (2019) | This study was funded by the |
| 084113/Z/07/Z | Wellcome Trust | Prof Adrian Hill | 07/11/2007 | £3,400,000.00 | £ 3,400,000.00 | de Cassan et al (2011) | S.C.d.C. is a Ph.D. student supj |
| 084113/Z/07/Z | Wellcome Trust | Prof Adrian Hill | 07/11/2007 | £3,400,000.00 | £ 3,400,000.00 | Payne (2017) | This work was supported by a |
| 106325/Z/14/A | Wellcome Trust | A.V.S Hill | 19/12/2014 | £2,100,000.00 | £ 2,100,000.00 | Venkatraman N (2019) | This work was supported |
| 106917/Z/15/Z | Wellcome Trust | Draper SJ | 01/04/2015 | £1,901,424.00 | £ 1,901,424.00 | Payne (2017) | This work was supported by a |
| 097395/Z/11/Z | Wellcome Trust | Reyes-Sandoval A | 12/12/2011 | £1,081,461.00 | £ 1,081,461.00 | Atcheson (2018) | The work was funded by a We |
| 108734/Z/15/Z | Wellcome Trust | Rawlinson TA | 24/06/2015 | £271,399.00 | £ 271,399.00 | Payne (2017) | This work was supported by a |
| - | Wellcome Trust | A.V.S Hill | - | - | - | Bowyer (2018) | The clinical trial was supporte |
| - | Wellcome Trust | Gola A | - | - | - | Gola (2018) | A.G. is funded by the Wellcor |
| - | Wellcome Trust | - | - | - | - | Mensah (2017) | This work was supported by a |
| - | Wellcome Trust Clinical Research Facilit | - | - | - | - | Barnes et al (2012) | European Union (Framework' |